


Cumulative Index

VOLUMES 4-6

JANUARY, 1967-NOVEMBER, 1969



Cumulative Index

Abdominal pain
in hereditary hemorrhagic disease, 5:56-57
postoperative, 5:1155-1156, 1174-1175, 1177
regional-block therapy for, 5:1182

Abortion
defibrillation and, 5:417-418
water and electrolyte disturbances in, 5:721-723, 725-726

Abruptio placentae, defibrillation and, 5:401-411

Acetaminophen in treatment of pain, 5:1106-1107

Acetazolamide
dosage and preparation of, 6:1228
epilepsy and, 6:1224
side-effects of, 6:1228-1227

Achilles tendon reflex, thyroid hormone and, 6:461

Achondroplasia, 5:237

Acid-base balance
description of, 5:635-639
in poisoning, 4:609, 649-652, 656-657, 676
in surgical patients, 5:709-713
See also Acidosis; Alkalosis

Acidosis
azotemia with, 5:632-634
in burn patients, 4:1204, 1219-1220
correction of, 4:1220-1221
causes of, 5:641-642
diabetic, *see* Diabetic ketoacidosis
in infants, 5:690-692
metabolic, 5:642-653; 6:320-321
causes, 5:643
correction, 4:516-517, 518; 5:647-653
in shock, 4:295
in surgical patients, 5:710-711
treatment, 5:647-653

in renal failure, 6:1039

renal tubular, 4:515-521

respiratory, 5:653-655; 6:34-35, 82, 261-270, 276, 317, 320, 350

in emphysema, 6:269-270, 337, 339-340

I.P.P.B. in, 6:98-102

pCO₂ and, 6:243

in surgical patients, 5:711-713

therapy for, 6:269-270, 347, 354-356

Aciduria, hereditary orotic, 4:1037

Acoustic neuroma (neurinoma), vertigo and, 6:576-579, 613

Acrocyanosis, 4:382

Actinomycosis, 6:1124-1126

Activated charcoal therapy for neuropathy, 5:1246

Addison's disease, 5:179-183
morphine dosage with, 5:1141

Adenomas
islet-cell, 4:1001
thyroid, 6:535

Adipose tissue, 4:1083-1088
lipid mobilization from, 4:1087-1090
metabolism of, and obesity, 4:1083-1094
reduction of heat loss and, 4:1149

ADL (activities of daily living) test, 5:896

of stroke patients, 5:978, 980-981

Adolescence
changes of health in, 6:648-649
delayed, 5:226-228
hemophilia in, 5:121-123
psychotropic drug hazards in, 6:795
testicular androgen deficiency in, 5:189-195

Adrenal cortex, diseases of
affecting growth, 5:168-183
potassium excess from, 5:668

Adrenal corticosteroids
in blood platelet disorders, 5:423
as nonspecific anti-inflammatory agents, 5:780
in obstructive pulmonary disease, 6:303-305, 356
psychotic reactions from, 6:740
purpura from, 5:454

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-668, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

- relative anti-inflammatory potency of, 5:874
- in treatment of allergy, 5:843-851
- in atopic dermatitis, 5:869-870, 871, 873-875
- in drug reactions, 5:811
- in emergencies, 5:788-789, 844
- in gastrointestinal allergy, 5:863
- hazards and complications, 5:838, 848-850
- side effects, 5:843, 847-848
- in urticaria, 5:833, 844
- See also* Corticosteroid therapy; Steroid therapy
- Adrenal hyperplasia, congenital, 5:168-174
- Adrenal steroid therapy in idiopathic chronic insulin resistance, 4:19-21
- Adrenocorticotrophic hormone therapy for Bell's palsy, 5:1281-1282
- for postinfectious neuropathy, 5:1264
- Aerosol therapy in bronchopulmonary disease, 6:361-370
- Afibrinogenemia, congenital
- surgical care in, 5:78-79
- therapy for, 5:51-52
- Agranulocytosis as drug side-effect, 5:1108, 1118, 1273
- Airway and respiratory care of neuropathic patient, 5:1214
- in postinfectious neuropathy, 5:1265
- Airway obstruction
- aerosol therapy, 6:361-370
- cor pulmonale in, 6:248-260
- definition of, 6:12, 233
- hypoventilation and, 6:83
- management of secretions, 6:297-300, 353-354
- recognition of, 6:47
- reduction of, in obese, 4:1173-1175
- respiratory acidosis and, 6:98
- tests for, 6:233-247
- therapy for infectious, 6:322-324, 354
- tracheal intubation and tracheotomy in, 6:47-60
- Akinetic seizures, 6:1220
- Albinism, bleeding in, 5:448
- Albright's Sebright-Banton syndrome, 5:230-237
- Albuminuria as reaction to salicylates, 5:1103
- Alcoholic cirrhosis, *see* Cirrhosis—alcoholic
- Alcoholic neuropathy, 5:1249-1262
- complications of, 5:1254
- convalescent and long-term care of, 5:1260
- prognosis for, 5:1260-1261
- protection of patient with, 5:1213
- therapy for
- auxiliary therapeutic measures, 5:1259-1260
- basis and scope of therapy, 5:1249-1250
- specific therapeutic measures, 5:1250-1259
- Alcoholics Anonymous, 6:764, 768, 770-773
- Alcoholism, 6:760-766
- diagnosis of, 6:760-762
- hand in, 6:665-666
- magnesium deficiency with, 5:671
- menopausal osteoporosis and, 5:577
- sociopathy compared to, 6:708-709
- treatment of, 6:762-775
- clergyman's role, 6:890-891
- drugs, 6:774-775
- family therapy, 6:772-773
- group therapy, 6:768-772
- relapse, 6:765-768
- resistance to treatment, 6:763-764
- withdrawal in, 6:740-742
- Aldosteronism
- magnesium deficiency with, 5:671
- potassium deficiency with, 5:665
- Alkalosis in poisoning, 4:729-733
- Alkaloids in Parkinson's disease, 5:284, 293, 295
- Alkalosis
- causes of, 5:642
- metabolic, 5:655-660; 6:320
- in surgical patient, 5:710
- treatment, 5:658-660
- respiratory, 5:660-661; 6:271-276, 320
- Allergic emergencies, 5:775, 782-791
- antihistamines in, 5:789, 842
- corticosteroids in, 5:788-789, 844
- in food allergy, 5:859-860
- Allergic reactions
- to analgesics, 5:1103, 1112, 1115, 1118
- definition of, 5:777
- types of, 5:777-781
- anaphylactic, *see* Anaphylaxis
- Allopurinol for uric acid stones, 4:532-538
- Alpha-acid glucosidase deficiency, 4:1002
- Alpha-adrenergic blocking agent, 4:247-248, 374, 380-381
- Alpha-beta concept, 4:247-248
- Alphaprodine, 5:1144, 1145

for labor pain, 5:1144, 1145
for postoperative pain, 5:1160, 1176
Aluminum salicylates in treatment of
pain, 5:1099, 1101
Alveolar-capillary block syndrome,
treatment in, 6:103-117
Alveolar hypoventilation, *see* Alkalosis—respiratory
Alveolar proteinosis, treatment of,
6:109
Amebiasis
 hepatic, 6:153-155
 with pericarditis, 4:150-151
American Diabetes Association, food
exchange system of, 4:1132-
1134
Amino acid metabolism, disorders of,
4:1030-1031
 mental retardation and, 4:1019-1029
Aminopyrine therapy for pain, 5:1108
Ammonia
 intoxication from, and congenital
 lysine intolerance, 4:1030-
 1031
 in poisoning, 4:638
Amniotic fluid embolism and defibrination, 5:415-417
Amphetamine therapy
 in obesity, 4:1138-1141
 for pain, 5:1116, 1118, 1119, 1124
 in Parkinson's disease, 5:293, 297
Amphetamines, 6:803-804
 users of, 6:714-715
Amphotericin B therapy
 anemia from, 4:953
 in cryptococcus meningitis, 4:956-958
 for histoplasma pericarditis, 4149-150
 in mycotic meningitis, 4:951, 952,
 959
 renal failure from, 4:953
 in systemic fungal infections, 4:951-
 959
Amputations
 lower-extremity, 4:416-441
 bilateral, 4:434-435
 gait training in, 4:433-435
 above knee, 4:420-421
 below knee, 4:419-420
 optimum level of, 4:418-421
 postoperative measures, 4:421-425

preoperative measures, 4:416-418
prosthesis, 4:421-425, 427-433,
 439-440
reasons for, 5:1047, 1048
rehabilitation after, 5:1047-1055
sites of, 5:1048-1049
Amyloidosis, 5:1233-1234
 following immunization, 5:881
Amyotrophic lateral sclerosis, 5:1003
Amyotrophy, 5:1229
Anal pain, therapy for, 5:1185
Analgesic therapy
 antipyretic and anti-inflammatory
 combined antipyretics and nar-
 cotics, 5:1117-1118
 varieties, 5:1095-1110
 combinations and mixtures of,
 5:1116-1119
 drug interactions, 5:1162
 drug tolerance and, 5:1129
 side effects, 5:1118-1119
 mild, 5:1094-1120
 classification by drug activity,
 5:1095-1116
 criteria for drug use, 5:1094-1095
 non-narcotics, 5:1110-1114
 for neuropathy, 5:1235, 1239, 1250,
 1266
for obstetric and gynecologic pa-
 tients, 5:1164-1179
 alphaprodine, 5:1145, 1171
 labor pain, 5:1165-1171
 meperidine, 5:1144, 1171
 postoperative pain in gynecologic
 patients, 5:1174-1177
 postpartum pain, 5:1172-1174
for postoperative pain, 5:1156
 choice of drug, 5:1160, 1162
 drug administration, 5:1154-1155,
 1158, 1159
 of gynecologic patients, 5:1174-
 1177
 side-effects, 5:1157
potent drug forms for, 5:1136-1150
regional anesthetic, 5:1181
See also Narcotic analgesic therapy;
 specific analgesics
Anaphylaxis, 5:775, 782-791
 clinical manifestations of, 5:782-783
 as drug reaction, 5:1103, 1112

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May;
pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May;
pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May;
pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

etiology of, 5:786-787
 fundamental mechanism of, 5:778,
 783
 from immunization, 5:881-882
 prophylaxis against, 5:789-790
 treatment of, 5:787-789
 antihistamines contraindicated,
 5:839, 840
 corticosteroids, 5:788-789, 844,
 845
 Androgen therapy for menopause,
 5:552-554, 558-559
 osteoporosis treatment, 5:553-554
 Anemia, 4:671
 after amphotericin B therapy, 4:953
 aplastic, 5:1108, 1273
 thrombocytopenia with, 5:435-436
 hemolytic, drug-induced, 5:1105-
 1106
 iron-deficiency, 5:1102
 pernicious, mental retardation and,
 4:1038-1039
 in pyrogenic meningitis, 4:902
 pyridoxine-responsive, 5:1258
 of renal failure, 6:1028-1029, 1036-
 1038
 Anesthesia
 conduction, labor pain and, 5:1168
 timing for conduction anesthesia,
 5:1171
 postoperative pain and, 5:1155, 1157,
 1158-1159
 regional (local), *see* Regional-block
 therapy
 Aneurysm, false, 4:409
 Angina pectoris, pain with, 5:1085,
 1087, 1089
 Angioneurotic edema
 as drug reaction, 5:1103, 1112
 hereditary, 5:830
 Angiosarcoma, treatment of, 6:418-419
 Anhidrosis and diabetes, 4:58-59
 Anileridine therapy, 5:1144, 1145
 Aniline derivative therapy, 5:1104-1107
 side-effects of, 5:1105-1107, 1118
 Ankylosing spondylitis, 5:1011
 rehabilitation in, 5:1015-1016
 respiratory failure with 6:39
 Anniversaries and changes in health,
 6:650
 Anorexiant drugs in obesity, 4:1138-
 1142
 Anterior root intrathecal phenol block
 therapy, 5:1183
 Anterolateral cordotomy, pain relief
 from
 of cervical region, 5:1201
 thoracic, 5:1200
 Antibiotic therapy
 for brain swelling, 4:968
 for diabetic patients, 4:115-116
 in gangrene, diabetic, 4:104-105
 in meningococcal meningitis, 4:934-
 936
 in neonatal meningitis, 4:911-914
 in neurogenic vesical dysfunction,
 4:53
 in oral ulcerations, 4:558-559, 567-
 569
 in poisoning, 4:605
 in postpericardiotomy syndrome,
 4:174
 in purulent pericarditis, 4:139-141
 in pyogenic meningitis, 4:900, 902-
 906, 920-926
 in tuberculosis meningitis, 4:939-942
 in tuberculosis pericarditis, 4:183-187
 in urinary infections, 4:507-510
 in viral meningitis, 4:96
 Anticholinergic drugs
 in gastrointestinal allergy, 5:862-863
 in Parkinson's disease, 5:285-294, 318
 Anticoagulant therapy
 in arterial disorders, 4:358-361
 in arteriosclerosis obliterans, 4:96
 in coronary artery disease (diabetic),
 4:99
 in diabetes, 4:95, 115
 in pericarditis of acute myocardial
 infarction, 4:177
 in postinfarction syndrome, 4:179
 Anticoagulants, circulating, 5:26-27,
 58-59
 Antidotes for poisoning, 4:605, 616-624
 Antihistaminic drugs, 5:780
 in Parkinson's disease, 5:285-286,
 293, 296
 in treatment of allergy, 5:837-843,
 850
 in atopic dermatitis, 5:875
 in drug reactions, 5:811
 in emergencies, 5:789, 842
 in gastrointestinal allergy, 5:862
 in urticaria, 5:831-833, 834, 835,
 838, 841
 types of, 5:840-842
 Antipyrine therapy for pain, 5:1108
 Aortography, 4:395, 397
 Aortoiliac arteriosclerosis, surgery for,
 4:386-389
 A.P.C. (aspirin, phenacetin, caffeine)
 therapy for pain, 5:1114,
 1116, 1118
 side-effects of, 5:1119
 Aphasia
 childhood, 4:797-799

diagnosis of, 6:875-877

Apresoline-induced neuropathy, 5:1239

Aphthae, recurrent (aphthous stomatitis, recurrent), 4:558-559

Arboviruses, 6:1146-1147

Arrhythmia, 6:1193

Arm pain

- neuropathic, 5:1215-1221
- regional-block therapy for, 5:1185

Arsenic neuropathy, 5:1240-1242

Angiography

- air studies in epilepsy and, 6:1212-1212
- peripheral, in diabetic atherosclerosis, 4:114

Arteriosclerosis, occlusive

- anticoagulant therapy for, 4:358-361
- aortoiliac, 4:386-399
- care of extremities in, 4:354-357
- femoral, 4:386-394, 399-400
- ischemic neuropathy with, 5:1267
- physical activity with, 4:351-353, 361-362
- surgery for

 - aortoiliac, 4:394, 397-399
 - complications, 4:401-403
 - contraindications, 4:394
 - femoral artery, 4:399-400
 - indications, 4:386-393

- with tropic changes

 - demarcation of lesion, 4:361-362
 - healing, 4:366-367
 - increase in circulation, 4:362-365
 - physical activity, 4:361-362
 - preventing spread, 4:365

Arteriosclerosis, renal, in diabetic nephropathy, 4:142

Arteriosclerosis obliterans

- anticoagulant therapy for, 4:358-359
- care of extremities in, 4:354-357
- diabetes and, 4:95-96, 103
- intermittent claudication in, 4:352-353, 376-377
- ischemic neuritis in, 4:358
- smoking with, 4:358
- surgery for, 4:386-387
- vasodilator drugs for, 4:376-378

Arteriosclerotic heart disease

- weight reduction in, 4:1143-1144
- See also* Coronary heart disease

Arthritis

- analgesic therapy for, 5:1095
- antibiotics in, 6:1071-1080, 1087-1089, 1095-1097
- for children, 6:1104-1109
- gonococcal arthritis, 6:1135-1137
- in children, 6:1102-1116
- gonococcal, 6:1132
- drainage of joints in, 6:1068, 1089-1090, 1093-1101, 1128
- in children, 6:1109-1112
- gonococcal, 6:1130-1139
- hand in, 6:666
- monitoring treatment of, 6:1081-1092
- mycobacterial and fungal forms of, 6:1117-1129
- caused by atypical mycobacteria, 6:1123-1124
- mycotic, 6:1124-1128
- tuberculosis, 6:1113-1114, 1117-1123
- reasons for failure in treatment of, 6:1067
- reconstruction of joints in, 6:1099-1100
- rehabilitation in, 5:1010-1021
- acute traumatic joint, 5:1020
- arthritis of unknown etiology, 5:1011-1019
- degenerative joint disease, 5:1019-1020
- infectious arthritis, 5:1010-1011
- metabolic arthritis, 5:1020-1021
- Reiter's syndrome, 6:1140-1145, 1150, 1151
- rheumatoid, *see* Rheumatoid arthritis
- steroid therapy for, 5:1126
- viral forms of, 6:1146-1153

Arthropathy, neurogenic, with diabetes, 4:55-56

Articulation, 4:783

Ascariasis, treatment of, 6:157

Ascites, 6:191-199

- genesis of, 6:178, 191, 193
- treatment of, 6:193-199

Aspirin therapy for pain, 5:1096-1103

- in analgesic combinations, 5:1117-1118, 1129
- postpartum pain, 5:1172, 1173
- side effects of, 5:1101-1103

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

special aspirin forms for, 5:1097-1101, 1173

Asthma, 6:230, 233, 278-330
 bronchial, *see* Bronchial asthma
 clinical classification of, 6:279-285
 definition of, 6:279
 as drug reaction, 5:1103
 immunologic mechanisms in, 6:284-285

laboratory studies in, 6:285-287
 mortality in, 6:278-279, 283-284
 perennial, in food allergy, 5:852-853
 physiology of, 6:287-294
 spirogram patterns in, 6:234
 status asthmaticus, 5:782; 6:230, 279, 294-325, 354, 356-357
 acid-base disorders, 6:317-322
 antihistamine therapy, 6:324
 case study, 6:292-294
 clinical data, 6:281-282
 corticosteroids in, 5:845-846
 definition, 6:294
 drug therapy, 6:300-306, 350, 351
 gas exchange adequacy, 6:306-317, 357
 management of secretions, 6:297-300
 pathology, 6:282-284
 therapy of infections, 6:322-324

Ataxia, speech in, 4:797

Atelectasis
 avoidance of, in burned patient, 4:1274-1275
 postoperative pain and, 5:1175

Atherosclerosis
 menopause and, 5:581-586
 occlusive, in diabetic, 4:111-113
 drug therapy for, 4:115-116
 peripheral arteriography for, 4:114
 prognosis for, 4:118
 prophylaxis for, 4:115
 pulse wave oscillography and, 4:114
 surgery for, 4:116-118
 primary biliary cirrhosis and, 6:212-213
 vertigo from, 6:569-570

Athetosis
 speech in, 4:797
 surgery for, 5:313-314

ATN (acute tubular necrosis), *see* Renal failure

Atopic dermatitis, 5:866-878
 complications of, 5:876-877
 differential diagnosis of, 5:866-867
 identifying specific allergen in, 5:867-869
 treatment of, 5:869-878

whether an allergic disease, 5:775, 867

Atropine
 in Parkinson's disease, 5:285, 286, 291
 for toxic neuropathy, 5:1244-1245, 1247

Autism, infantile, 4:775

Autoerythrocyte sensitization, 5:30-31, 459-460

Autonomic neuropathy, 5:1229-1230

Autonomic seizures, 6:1221-1222

Autosomes, 4:838

Axillary neuropathy, 5:1216-1217

Azotemia
 dietary sodium in treatment of, 5:626-634
 magnesium deficiency with, 5:671

Back pain
 low, *see* Low back pain
 regional-block therapy for, 5:1182

BAL (British anti-lewisite, 2,3-dimer-captopropanol)
 in heavy-metal reactions, 5:810
 in Parkinson's disease, 5:322, 323-325

BAL therapy for neuropathy
 arsenic neuropathy, 5:1247
 thallium neuropathy, 5:1247

Barbiturates
 addiction, 6:713-714
 withdrawal from, 6:740
 in analgesic mixtures, 5:1116
 clinical pharmacology of, 4:679, 684
 dependence on, 5:1124
 narcotics and, for labor pain, 6:1166-1168
 physicochemical properties of, 4:680
 poisoning and, *see* Poisoning, barbiturate
See also Phenobarbital

Basal metabolic rate
 low, and reduction in caloric expenditure, 4:1127
 thyroid hormone and, 6:460

Base
 excess of, metabolic acidosis and, 5:656-657
 loss of, metabolic acidosis and, 5:647, 649-650

BCG vaccine, 5:888

Bedsonia, arthritis and, 6:1150, 1151

Behavioral changes after meningitis, 4:983

Behavioral responses to immobilization, 5:908

Belladonna alkaloids in Parkinson's disease, 5:284, 293, 295
Bell's palsy, 5:1278-1284
definitive medical therapy for, 5:1281-1282
general management of, 5:1279-1280
late complications of, 5:1283
special tests for, 5:1280-1281
surgical therapy for, 5:1282
Benzomorphan derivative therapy, 5:1147-1148
Beriberi, infantile, 4:1038
Bernard, Claude, 5:615
Beryliosis, 6:108
Beta-blocking agents, 4:247-248, 374-375, 381
Bile
composition and stability of, 5:483-488
in gallstone disease, 5:487-488
Bile ducts and gallstone formation, 5:488-489
Biliary pain, drug for, 5:1147
Biliary system, effect of morphine on, 5:1140
Biliary tract, postcholecystectomy complications of, 5:528-540
Bilirubin
decreased conjugation of, in newborn, 4:996-997
excretion of, gallbladder nonvisualization and, 5:501
unconjugated, and cerebral accumulation of, 4:995
Bis-mono-isopropylamino fluorophosphine oxide neuropathy, *see* Mipafox neuropathy
Bladder
atonic, 5:1229
care of neuropathic patient's, 5:1214, 1235
distended, 5:1088
disturbance of function of, 5:1180, 1199
dysfunction of, in diabetic neuropathy, 4:51-54
loss of control of, 5:1090
paralysis of, 5:1231
rupture of, 6:934
Blastomycosis, 6:1124, 1125
Bleaches as poison, 4:638-641
Bleeding
gastrointestinal, in burned patient, 4:1286-1287
See also Blood; Hemorrhage
Bleeding time, prolonged, as drug side-effect, 5:1102-1103
Blepharospasm in Parkinson's disease, 5:319
Blindness, *see* Vision, loss of
Blood
arterial lactate in shock and, 4:281, 289-290
flow of, mechanism of, 4:371-372
gases in, in shock, 4:281, 296
occult loss of, as drug side-effect, 5:1101-1102
red cells of, 4:267-268
volume of, effect of surgery on, 5:1152
Blood coagulation
defects of
acquired, 5:24-37, 363-383; *see also* Defibrillation syndromes
aggravation of, 5:1118
hereditary disorders of
dental care, 5:93-110
diagnosis, 5:22-24, 33
genetic counseling, 5:125-133
psychiatric and social care, 5:111-124
surgical care, 5:61-83
therapy, 5:39-60
Blood dyscrasias from drugs, 5:1106, 1109
Blood levels
of drugs, 5:1097-1098, 1100, 1104
of sugar, *see* Glucose in blood
Blood lipids, regulation of, 6:1302-1304
cholesterol, 6:1304-1306
fatty acids and triglycerides, 6:1306-1309
hypolipemic drugs, 6:1310-1311
liver disease and, 6:1352-1358
phospholipids, 6:1309-1310
Blood pH, measurement of, 5:640-641
Blood platelet disorders, 5:27-30, 95-96, 423-444

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-768, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

- with bone-marrow disorders, 5:435-436
- after transfusions, 5:436-440
 - See also specific disorders*
- Blood pressure
 - in shock, 4:281
 - transient fall in, 5:1254
 - variation of, as drug side-effect, 5:1158
- Body water, 5:617-624
 - baseline requirements for, 5:700
 - cellular, 5:621-624
 - extracellular, 5:618-621
 - potassium excess and, 5:667
 - of infants
 - amount, 5:617, 684-685
 - requirements, 5:685-688
 - magnesium deficiency from loss of, 5:670
 - See also Fluid and electrolyte disorders; Water intoxication*
- Bowels
 - care of neuropathic patient's, 5:1214
 - dysfunction of
 - from regional blocks, 5:1180
 - See also Constipation; Diarrhea*
- Brachial plexus neuropathy, 5:1215-1216
- Bradykinesia, testing for, 5:259-260, 279
- Brain
 - abscess of, and meningitis, 4:978
 - emotional-response structures in, 5:1198-1199, 1202
 - intracranial pressure in, increased in pyrogenic meningitis, 4:900-901, 924-925
 - morphine distribution to, 5:1139
 - neuropathies affecting, 5:1231, 1232
 - sterotoxic thalamotomy on, 5:1206
 - swelling of, *see* Edema—cerebral in tuberculosis meningitis, 4:944-945
 - See also specific parts of brain*
- Brain damage, 5:942-948
 - congenital, 5:944-947
 - psychologic examination in, 5:896-897
 - traumatic, 5:942-944
 - social reintegration of patient, 5:943-944
- See also Stroke patients*
- Brain scan in epilepsy
- radio pharmaceuticals, and, 6:1208-1209
 - results of, 6:1209-1212
- Bromide intoxication, withdrawal from, 6:739-740
- Bronchial asthma
 - antihistamines in, 5:839
 - corticosteroids in, 5:844, 845
 - in drug allergy, 5:805
 - meperidine therapy for, 5:1144
 - morphine therapy for, 5:1141
- Bronchiectasis, *cor pulmonale* and, 6:249
- Bronchitis, 6:233, 354
 - chronic, acidosis from, 5:653
 - cor pulmonale* and, 6:249
- Bronchodilating drugs, 6:351-353
 - aerosols, 6:364
- Bronchodilation in airway obstruction, 4:1177
 - for burned patients, 4:1270
- Bronchoscopy in status asthmaticus, 6:295-296
- Bronchospasm
 - anaphylactic, 5:783, 784
 - treatment, 5:787, 789, 817
 - in burned patient, 4:1270
- Bruits in arterial obstruction, 4:389-392
- Buerger's disease, neuropathy with, 5:1267
- Buffered salicylate therapy for pain, 5:1098, 1101
- Burns
 - acute brain syndromes following, 4:1294
 - airway establishment with, 4:1263, 1267-1268
 - assisted ventilation, 4:1269
 - tracheal humidifier, 4:1269-1269
 - tracheostomy for, 4:1268-1269
 - airway trauma with, 4:1204
 - aldosterone activity with, 4:1207
 - blood volume reduction in, 4:1206
 - cause of, 4:1196
 - cell damage in, 4:1198, 1204
 - in children, 4:1298-1300
 - cold applications for, 4:1198, 1224
 - cold water treatment of, 4:1200-1202
 - colloid therapy for, 4:1232-1233, 1236, 1241
 - formulas for predicting colloid requirements, 4:1240-1241
 - initial infusion, 4:1236, 1240
 - urine volume, hourly measurement, 4:1240
 - constricting, 4:1305
 - deep, partial thickness of, 4:1307
 - depth of, 4:1196-1197
 - diagnosis of, 4:1245-1246
 - edema formation with, 4:1198, 1204, 1206
 - bronchial, 4:1270
 - encephalopathy and, related to in-

jury, 4:1293-1294

eschar
chemical debridement of, 4:1305-1306
mechanical debridement of, 4:1306-1307
evaluation of, 4:1196-1202
extent of body surface burned, 4:1196, 1246-1247
first-degree, 4:1243, 1248
fluid therapy for, 4:1196-1197
after initial replacement and resuscitation, 4:1230-1231
albumin in low-sodium diluent, 4:1219
balanced electrolyte solutions, 4:1221-1224
contraindicated in pulmonary-burn patients, 4:1278
for correction of acidosis, 4:1220-1221
dextran in saline, 4:1219
experimental and clinical basis, 4:1208-1218
formulas for predicting requirements, 4:1240-1241
initial, 4:1224-1226
laboratory studies, 4:1226-1229
plasma, 4:1214, 1219
plasmanate, 4:1219
rapid, and resultant edema, 4:1224-1225
sodium acetate, 4:1220
sodium bicarbonate, 4:1220, 1221
sodium chloride solution, 4:1219-1220
sodium lactate, 4:1220, 1221
whole blood, 4:1218-1219
gastrointestinal bleeding with, 4:1286-1287
hand, 4:1311
hospital discharge and, 4:1296-1298
hospital treatment of and recovery from, 4:1294-1296
hypnotic therapy for, 4:1301-1302
intracellular enzyme production in, 4:1204
of joints, 4:1311
late care of, 4:1312
local therapy for, 4:1242-1261

long-term management of, 4:1282-1289
metabolic acidosis with, 4:1207, 1220
neck, 4:1311
nutrition of patient with, 4:1285-1286
pain relief with, 4:1197-1198
pathophysiology of, 4:1203-1208
plastic therapy for, indications for, 4:1304-1312
positioning and splinting for, 4:1287-1289
potassium loss with, 4:1204
replacement therapy, 4:1223
primary excision for, 4:1304-1305
psychotherapeutic support of patient with, 4:1291-1302
in period of acute crisis, 4:1291-1294
role of psychiatrist, 4:1300-1302
pulmonary problems with, 4:1264-1266
avoidance of atelectasis, 4:1274-1275
bronchial edema, 4:1270
bronchospasm, 4:1270
clinical care, 4:1267-1278
edema phase (0-24 hours), 4:1266-1267
fluid therapy and lungs, 4:1278
heat and flame, 4:1264-1265
intratracheal antibiotic therapy, 4:1277
physical findings, 4:1265-1266
pneumonia phase (14-28 days), 4:1267
removal of noxious gases, 4:1272-1274
re-oxygenation, 4:1270-1272
sepsis, control of, 4:1275-1277
smoke and irritating gases, 4:1264
tissue slough and sepsis phase (3-14 days), 4:1267
replacement of fluid loss from, 5:704
respiratory problems with, 4:1263-1279
resuscitation from, systemic therapy for, 4:1203-1233
"rule of nines" and, 4:1243-1244, 1248

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-804, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

second-degree, 4:1243-1244, 1248
 skin grafts for, 4:1307-1311
 sodium loss from, after first 48 hours, 4:1231-1232
 third-degree, 4:1244-1245, 1248
 unhealed old, 4:1312
 excision of, delayed and staged, 4:1250-1251
 excision of, immediate, 4:1249-1250
 exposure method of treatment, 4:1253-1255
 first-aid therapy, 4:1247-1248
 initial cleansing, 4:1248-1249
 local care of, aims and principles, 4:1247, 1249
 management of, long-term, 4:1282-1284
 occlusive dressings, 4:1251-1253
 pathology, 4:1242-1245
 topical antibacterial therapy, 4:1255-1261; *see also specific drugs*

Bursitis, septic prepatellar, 6:1112

Caffeine therapy for pain, 5:1116, 1117, 1119; *see also A.P.C. therapy for pain*

Calcium
 deficiency of, *see Hypoparathyroidism; Uremia*
 excess of, *see Hypercalcemia*
 idiopathic hypercalcioria and, 5:680
 menopausal osteoporosis and, 5:576-577, 680-681
 metabolic disorders of, 4:1007-1011
 in dialysis patient, 6:1062-1063
 in uremia, 6:1046-1049

Calculi, urinary (calcium stones), *see Kidney stones*

Caloric balance, positive, 4:1125-1127

Caloric-protein malnutrition, magnesium deficiency with, 5:671

Caloric tests, 6:601-602, 603-604

Caloric therapy for neuropathy, 5:1259

Calories, baseline requirement of, 5:701

Cancer
 clergymen and treatment of, 6:894-895
 drug tolerance and, 5:1128-1129
 metastatic hypercalcemia due to, 5:681-682
 pain with, control of, 5:1089-1091
 regional-block therapy, 5:1180
 surgical procedures, 5:1200, 1203
 terminal stage, 5:1091, 1125
 thyroid nodules and, 6:534-549
See also specific types of cancer

Canker sore (recurrent aphthous stomatitis), 4:558-559, 567-570

Carbamazepine therapy for neuralgia, 5:1273

Carbohydrate metabolism disorders, 4:997-1007
 in uremia, 6:1049-1050

Carbonic acid-bicarbonate system and pH, 5:639-640

Carcinoma
 breast, pulmonary insufficiency with, 6:111
 cervical, hopelessness predisposition and, 6:653
 chorio-, hyperthyroidism with, 6:513
 prostatic, lymphedema secondary to, 6:386
 thyroid
 from radioiodine treatment, 6:502-503
See also Cancer—thyroid nodules and
See also Cancer

Carcinomatous neuromyopathies, *see Neoplastic neuromyopathies*

Cardiac arrest
 anaphylactic, 5:783
 treatment, 5:788, 789
 from poisoning, 4:608

Cardiac arrhythmia, vertigo and, 6:572, 574-575

Cardiac deficit in shock, 4:282-284

Cardiac disability, 5:931-941
 balancing energy capacity and costs in, 5:932-935
 definitions of, 5:931-932
 exercise program in, 5:937-941
 physical rehabilitation in, 5:932-935
 social and psychological rehabilitation in, 5:936-937

Cardiac failure, *see Heart failure*

Cardiac output, measurement of, 4:279-280

Cardiac tamponade, 4:129-130, 147, 157

Cardiopulmonary disorders in obese patients, 4:1162-1179

Cardiopulmonary syndrome of obesity, 4:1164-1165

Cardiorespiratory functions in obesity, 4:1162-1163

Cardiovascular function, postoperative, 5:1156, 1158-1159

Cardiovascular problems
 from analgesics, 5:1157
 in obesity, 4:1443-1444

Cardiovascular system, 4:270-271
 effect of morphine on, 5:1140-1141

See also specific parts of cardiovascular system

Carisoprodol therapy for pain, 5:1115

Carpal tunnel syndrome with neuropathies, 5:1211, 1232, 1234

Cataracts, diabetic, 4:63

Cation-anion metabolic disorders and mental retardation, 4:1039, 1043

Causalgia, therapy for specific, 5:1088
surgical, 5:1024

Celiac plexus block therapy, 5:1182-1183, 1187, 1188

Cellular fluids, 5:621-624

Cellular type of reaction, fundamental mechanism of, 5:779-780

Cellulitis and septic arthritis complicating osteomyelitis, 6:1112-1113

Central nervous system bleeding into, 5:57
effect of continuous pain on, 5:1086
hypoxia effects on, 6:19-21
paroxysmal vertigo and, 6:1295-1296
postshunt disturbances of, 6:187
renal failure and, 6:1015, 1042-1044

Cerebral biopsy in epilepsy, indications for, 6:1213-1214

Cerebral deficit, diagnosis of, 6:872, 874-877

Cerebral palsy
rehabilitation in, 5:945-947
speech disorders of, 4:796-797

Cerebral surgery to relieve pain, 5:1201-1202

Cerebral vascular accidents, 5:1086

Cerebral vascular lesions, *see* Stroke patients

Cerebrospinal fluid examination
anticoagulation of CSF in, 4:881-883
cell counts in, 4:880-882, 885
Wright's stain, 4:883-884, 885-886
cellular response in CSF in, 4:933
CSF profile in, 4:879
infectious meningitides and, 4:891-895
noninfectious factors, 4:894
chloride ion determination in, 4:891
cultures of CSF in, 4:890
in epilepsy, 6:1183, 1195

immunofluorescent technique of, 4:884, 887, 889
lumbar puncture in, 4:880-881
effect on patient, 4:981-982
in meningoencephalitis, 4:879-896
positive blood reaction in, serologic test for syphilis and, 4:891
processing of CSF in, 4:880-891
protein determination in, 4:889
staining of cells in CSF in, 4:883-889
sugar determination in, 4:889

Cerebrovascular diseases in diabetic, 4:99-102

Cervical pain, regional-block therapy for, 5:1180

Cervical vertigo, 6:570-573, 575-576

Cesarean section, water and electrolyte disturbances after, 5:723

Charcot joint with diabetes, 4:55-56

Chelation for poisoning, 4:673-677, 710-711

Chemotherapy in fungal infections of CNS, 4:951-957

Chest (thoracic) pain
in pericarditis, 4:126-127, 137, 147, 153
postoperative, 5:1155-1156, 1174
regional-block therapy for, 5:1180, 1185

Childhood trauma, 6:648

Children
epilepsy in, 6:1182-1189
Graves' disease in, 6:511
infectious arthritis in, 6:1102-1116
gonococcal, 6:1132
"Chloride depletion alkalosis," 5:657-658
treatment of, 5:659

Chlorpropamide in maturity-onset diabetes in obese, 4:1187-1190

Cholangitis
acute bacterial, 5:535-536
ascending, cholecystitis with, 5:523-524
nonsuppurative destructive, *see* Cirrhosis—primary biliary sclerosing, 5:537

Cholecystectomy, 5:503-504
treatment after, 5:528-540
whether required, 5:494, 495-496

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

- in silent gallstones, 5:508-512
- Cholecystitis**
 - acute gaseous, 5:522
 - diagnosis of, 5:514-517
 - gallstones and, 5:480, 514-515
 - medical treatment of, 5:514-527
- Cholelithiasis, *see* Gallstone disease**
- Cholera vaccine, 5:887**
- Cholestasis, drug-induced, 6:144-146, 148-149**
- Cholesterol**
 - blood lipids and, 6:1304-1306
 - as cause of pericarditis, 4:158
- Cholesterolosis, 5:489**
- Choline salicylate therapy for pain, 5:1100, 1102**
- Cholinergic urticaria, 5:835**
- Christmas disease, 5:22-23**
 - orthopedic management in, 5:84-92
 - surgical care in, 5:72-74
 - therapy for, 5:48-49
- Chromosomes**
 - aberrations of, 4:843
 - studies of, 4:837-844
- Chylopericardium and pericarditis, 4:159**
- Circulatory failure, *see* Hypertension**
- Cirrhosis of the liver, 6:176-179**
 - alcoholic, 6:121-122, 165-174, 200
 - treatment, 6:193-199
- ascites in, 6:191-199**
 - genesis, 6:178, 191-193
- gastrointestinal bleeding in, 6:179-187**
- magnesium deficiency with, 5:671**
- primary biliary, 6:122, 205-214, 1355-1357**
 - steroid effect on, 6:145
- renal failure in, 6:200-203**
- Claudication, intermittent, in occlusive arterial disease, 4:113; *see also* specific disorders**
- Clergymen, assistance to physician by, 6:885-899**
- Clonorchiasis, treatment of, 6:156**
- Cocaine users, 6:714-715**
- Coccidioidomycosis, 6:1124-1128**
- Codeine, 5:1137, 1138, 1142**
 - dependence on, 5:1111, 1123
 - side-effect of, 5:1112
 - in treatment of pain, 5:1110-1114
 - analgesic combinations, 5:1117-1118, 1129
- Cogentin (benztropine methanesulfonate), 5:293, 295-296**
- Cogwheeling in Parkinson's disease, 5:269-270, 318**
- Cold, use of, in rehabilitation, 5:911-912**
- Cold urticaria, 5:834**
- Colic, control of acute pain of, 5:1086, 1087, 1095**
- Colitis, chronic ulcerative, morphine and, 5:1140**
- Collagen diseases**
 - restrictive pulmonary impairment in, 6:104-105
 - vascular diseases, 5:1268, 1279
- See also* specific collagen diseases**
- Coma**
 - hepatic, *see* Hepatic coma
 - midbrain involvement in, 4:969
 - in neonatal hypoglycemia, 4:993
 - from poisoning, 4:610-611, 684-685
 - in Reye's syndrome, 4:1005
 - in tuberculosis meningitis, 4:945-946, 947-948
- Common bile duct**
 - evaluation of, after cholecystectomy, 5:532-533
 - obstruction of
 - after cholecystectomy, 5:529, 533-535
 - with cholecystitis, 5:525
- Common peroneal neuropathy, 5:1223-1224**
- Compressive neuropathies, *see* Traumatic and compressive neuropathies**
- Concato's disease, 4:157**
- Conditioning, drug addiction as, 5:1123-1124**
- Congenital lysine intolerance and mental retardation, 4:1030-1031**
- Congestive heart failure, *see* Heart failure—congestive**
- Conjunctivitis, allergic**
 - antihistamines for, 5:838, 839
 - corticosteroids for, 5:844
- Connective tissue disorders**
 - hereditary, 5:447-448
 - restrictive ventilatory impairment in, 6:105-106
- Connective-tissue disease reactions from drugs, 5:805-806**
- Constipation**
 - with autonomic neuropathy, 5:1229-1230
 - from drugs, 5:1112, 1140
- Consumption coagulopathy, *see* Defibrillation syndromes**
- Contact dermatitis**
 - delayed type of reaction in, 5:780
 - differential diagnosis of, 5:866-867
- Continuous lidocaine block therapy, 5:1183**

Conversion symptoms, sociopathy compared to, 6:709

Convulsions from dextropropoxyphene, 5:1113

Convulsive disorders
in children, with bacterial meningitis, 4:901-902
corticosteroids and, 5:850
as early sign of meningitis, 4:971-972
in neonatal tetany, 4:994
from poisoning, 4:612-613, 614, 663
tuberculosis meningitis and, 4:943-944
See also Epilepsy

Cor pulmonale
causes of, 6:249-251
definition of, 6:248
in emphysema, 6:249, 342-343
obstructive respiratory disease and, 6:248-260, 357
restrictive respiratory failure and, 6:31-32
treatment of, 6:112-113, 258-260

Coronary artery, restriction of flow in dog's, 4:309-312

Coronary artery disease in diabetic, 4:97-99

Coronary heart disease
clergymen and treatment of, 6:895
gallstones and, 5:496, 497
See also Angina pectoris; Atherosclerosis; Myocardial infarction

Corticosteroid therapy
for acute idiopathic pericarditis of childhood, 4:190
with antibiotics, in pericarditis, 4:148
with antituberculous drugs, in pericarditis, 4:144-145
in infectious nonspecific pericarditis, 4:137-138
in pericarditis, with LE, 4:155
in postinfarction syndrome, 4:178-179
in postpericardiotomy syndrome, 4:173-174
in rheumatic pericarditis, 4:154
for septic shock, 4:329, 337
in tuberculous meningitis, 4:940-941
See also Adrenal corticosteroids

Cosmetics, poisoning from, 4:643-646

Cough, aerosol therapy for, 6:369-370

Coumarin drugs, hemorrhagic complications from, 5:372-374

Cretinism, 4:1044-1046

Cryoglobulinemia, 5:35-36, 458-459

Cryptococcosis, 6:1124, 1125

Cushing's syndrome
childhood obesity and, 4:1152
potassium depletion with, 5:665
as side-effect of adrenal steroid therapy, 4:20

Cyanosis, hypoxia and, 6:18-19

Cycles, changes in health and, 6:649-650

Cystathioninuria, 4:1034-1035

Cystic duct remnants after cholecystectomy, 5:536

Cystine
crystals of, 4:541
cystine stone disease, 4:465, 470, 539-548; *see also* Kidney stones
tests for, 4:539-540, 550

Cystinuria, 4:539-552

Cysts, pericardial, 4:208-209

Cytotoxic (cytolytic) reactions, fundamental mechanism of, 5:778-779

DDT neuropathy, 5:1247

Defibrillation syndromes
laboratory diagnosis of, 5:388-389
mechanism of, 5:387-388
nonobstetric varieties of, 5:386-387
pathophysiology of, 5:385-386
prognosis in, 5:398
treatment of, 5:384-400

Deficiency neuropathy, 5:1249-1262
complications of, 5:1254
convalescent and long-term care of, 5:1260
prognosis for, 5:1260-1261
therapy for, *see* Alcoholic neuropathy—therapy for

Degenerative neurologic disease, 5:1003-1009; *see also* Parkinson's disease

Dehydration
in infants, 5:589-697

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

in labor, prevention of, 5:720
 in poisoning, 4:652
 in surgical patients, 5:705-708

Delayed type of reactions, fundamental mechanism of, 5:779-780

Delirium, 6:737-739

Demerol, *see* Meperidine

Dental care in hereditary disorders of blood coagulation, 5:93-110

Depression
 in acute illness, 6:736-737
 in children, 4:775
 circulatory, from poisoning, 4:687-689
 etiology of, 4:545-546
 masked, 6:688-694
 psychotropic drugs in, 6:795-796, 801-804
 signs of, 6:688-689
 sociopathy compared to, 6:709

Deprivation
 cultural, 4:760-761
 emotional, 4:760-761, 775

Dermatitis
 atopic, *see* Atopic dermatitis
 contact, *see* Contact dermatitis
 differential diagnosis of, 5:866-867
 medicamentosa, 5:801-803

Dermatophytosis with lymphangitis, 6:392-393

Dermographism, 5:833

Detergents as poison, 4:633-638

Development, *see* Growth

Dextran-40 for shock, 4:265, 266, 267, 272-273, 293, 328

Dextran-80 for shock, 4:265, 293

Dextroamphetamine therapy in obesity, 4:1142-1143

Dextropropoxyphene
 dependence upon, 5:1113
 side-effects of, 5:1113-1114
 in treatment of pain, 5:1112-1114
 analgesic combinations, 5:1117
 postpartum pain, 5:1173-1174

Diabetes
 corticosteroids in, 5:848
 gallstones and, 5:497
 neuropathy with, 5:1220, 1279
 pre-diabetes, 4:1181
 renal failure in, 6:1026

Diabetes insipidus, nephrogenic, 4:1046-1047

Diabetes mellitus, 4:87-88
 arteriosclerotic complications of, 4:85-88

Charcot joint and, 4:55-56

cerebral vascular disease and, 4:99-102

coronary artery disease and, 4:97-98

diarrhea in, 4:49-51

exercise in, 4:94

eye changes in, 4:62-67

gangrene in, 4:102-106, 113, 114

hemochromatosis in, 4:83

hemorrhage (ocular) in, 4:65-66

impotence in, 4:54-55

insulin in, *see* Insulin

obesity and, 4:25-26

occlusive atherosclerosis and, 4:113

resistant, treatment of, 4:16-29

skin changes with, 4:82-83

skin changes suggesting, 4:75-82

skin diseases associated with, 4:73-84; *see also* specific skin diseases

smoking in, 4:94

vascular complications with, 4:85-106; *see also* specific vascular diseases

Diabetes mellitus neuropathy, 4:59, 5:1226-1230
 with acromegaly, 5:1232

lateral femoral cutaneous neuropathy with, 5:1223

orthostatic hypertension, 4:57-58

somatic, 4:44-47

treatment of, 4:44-60

varieties of, 5:1227-1230

visceral, 4:47-59, 111

Diabetic ketoacidosis, 5:644
 chronic insulin resistance with, 4:24-25

from inadequate antibodies, 4:25-27

magnesium deficiency with, 5:671

treatment of, 5:650-651

Diagnosis
 double, 6:663-664

psychologist's evaluation for, 6:871-885

tests for, role of, in deficiency neuropathy, 5:1254-1255

Dialysis, 6:923, 946-949, 1054-1063
 in the home, 6:984-999, 1058-1063

peritoneal, for poisoning, 4:606, 664, 665-667, 694

for poisoning, 4:606, 693-694

types of artificial kidneys in, 6:1057-1058

Diarrhea
 diabetic, 4:45-59; 5:1229-1230
 in infants, water and electrolyte deficit from, 5:689-690

from mefenamic acid, 5:1109

metabolic acidosis in, 5:647

potassium depletion from, 5:665

Diathermy, 5:909-911

Diazepam
in degenerative neurologic disease, 5:1005-1006
dosage and preparation of, 6:1228
epilepsy and, 6:1224, 1225
side-effects of, 6:1226-1227

Dibenzazepines in Parkinson's disease, 5:293, 297

Diet
for citrullinemia, 4:1035
for cystinuria, 4:543, 551-552
for galactosemia, 4:1004-1005
for hereditary fructose intolerance, 4:1003
for homocystinuria, 4:1031
for hypercalcemia (idiopathic juvenile), 4:1007-1008
for kidney stones, 4:480-481, 482-485
for leucine-induced hypoglycemia, 4:998
for lipid-metabolism disorders, 4:1011
for maple syrup urine disease, 4:1030
for obesity, 4:1125-1137
in children, 4:1157-1158
for oxaluria, 4:527, 528-529
for phenylketonuria, 4:1032-1033
for renal tubular acidosis, 4:1032-1033

Digitalis
in congestive failure, 4:148-149
childhood, 4:190-192
in nonspecific pericarditis, 4:136, 208-209
in shock, 4:312-314

Dihydromorphinone therapy, 5:1137, 1138, 1142

Diphenylheptane derivative therapy, 5:1148-1149

Diphenylhydantoin (Dilantin)
dosage and preparation, 6:1228
epilepsy and, 6:1223
for neuralgia, 5:1272-1273
side-effects of, 6:1226-1227

Diphtheria, neurologic complications of, 5:1265-1266

Diphtheria vaccine, complications from, 5:885

Diplococcus pneumoniae, meningitis due to, 4:904-905, 918

Dipyrone therapy for pain, 5:1108

Disability
definition of, 5:891
superimposed, 5:906-908
See also Rehabilitation

Disease
onset of, importance of life setting for, 6:643-655
prevention of, 6:657

Disseminated intravascular coagulation, *see* Defibrillation syndromes

Disseminated lupus erythematosus (DLE), thrombocytopenic purpura with, 5:432

Disuse, complications of, 5:906-908

Dithizon (diphenyl thiocarbazone) therapy for neuropathy, 5:1247

Diuresis
forced, for poisoning, 4:664-665, 690-692
osmotic, in surgical patients, 5:705-706

Diuretics
in ascites treatment, 6:194-198
magnesium deficiency and, 5:670
potassium deficiency and, 5:665
in renal failure, 6:1024-1025
See also specific agents

Diverticula of pericardium, 4:208-209

Diverticulosis coli, gallstones and, 5:497

Dizziness, *see* Vertigo

Doctor-patient relationship, *see* Physician-patient relationship

DOPA (DL-dihydroxyphenylalanine) in Parkinson's disease, 5:255, 298

Down's syndrome
chromosomes in, 4:839
maternal age and, 4:848
probability and, 4:847-848
speech disorders in, 4:796

Drainage, pericardial, 4:139, 141

Dressler's syndrome in acute pericarditis, 4:128

Drug addiction (compulsive drug use)

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

to analgesics, 5:1136, 1141, 1142, 1144, 1147, 1176
 codeine, 5:1111, 1123
 morphine, 5:1139
 pentazocine, 5:1132
 clergyman's role in, 6:890-891
 as conditioned behavior, 5:1123-1124
 defined, 5:1121-1122
 placebo response and, 5:1128
 prevention of, 5:1123-1124, 1131
 recognition and management of, 6:704, 710-718
 resulting from medical treatment, 5:1122-1126, 1130, 1202
 patient's fear of addiction, 5:1129
 unrelated to painful illness, 5:1133
 withdrawal from, 6:742

Drug administration route for postoperative patient, 5:1157-1158

Drug allergy, 5:775, 792-813
 cytotoxic reactions in, 5:779
 description of, 5:794-796
 diagnosis of, 5:797-801
 skin tests, 5:799-800, 808-809
 in vitro tests, 5:800-801
 immunochemical mechanisms of, 5:796-797
 manifestations of, 5:801-806
 prevention of reactions from, 5:806-810
 desensitization, 5:780, 809
 "Medic-Alert" information, 5:790, 809-810
 records, 5:790, 809, 819
 toxic-complex type of reaction in, 5:779
 treatment of, 5:810-812
 emergency kit, 5:807
 urticaria treatment, 5:826-827

Drug combinations, *see* Analgesic drugs, combinations and mixtures of

Drug dependence
 on carisoprodol, 5:1115
 on codeine, 5:1111, 1123
 defined, 5:1122
 on dextropropoxyphene, 5:1113
 non-medical, 5:1132-1133
 on opiates, *see* Opiate dependence
See also Drug addiction

Drug-induced neuropathies, treatment of, 5:1237-1240
 general scope of treatment, 5:1237-1238
 varieties of neuropathies, 5:1238-1240

Drug interactions and postoperative pain, 5:1162

Drug reactions
 allergic, *see* Drug allergy
 classification of, 5:792-796
 definition of, 5:792-793

Drug tolerance
 toward morphine, 5:1139, 1141
 toward narcotics, 5:1121-1122
 cross-tolerance, 5:1129-1130
 developing, 5:1122
 management of, 5:1128-1129
 toward pentazocine, 5:1132

Drugs
 anticonvulsant, 6:1217, 1222-1231
 hyperkinesis and, 6:1236-1244
 labelling of, 5:808

Duchenne muscular dystrophy
 enzyme determination in, 5:1036
 rehabilitation in, 5:1039-1042
 types of, 5:1037-1039

Dwarfism, hypopituitary, 5:145-149

Dying patients
 clergymen and, 6:897-898
 management of, 6:746-759

Dysmenorrhea
 psychodynamic concepts of, oral contraceptives and, 5:587
 relief of pain of, 5:1095, 1116, 1204

Dyspepsia from drugs, 5:1101, 1109

Dysproteinemias, 5:455-459

Dysrhythmia, 6:1193

Dystonia musculorum deformans, surgery for, 5:314

Dystrophy, 5:1036-1046
 characteristics of, 5:1036-1037
 forms of, 5:1024-1045, 1233; *see also* Duchenne muscular dystrophy; Sympathetic dystrophies

Ears, pain in, surgical relief from, 5:1205

Echinococcus disease of the liver, treatment of, 6:157-160

Echocardiogram, 4:197-204

Echoencephalography in epilepsy, 6:1214-1215

Eczema
 antihistamines for, 5:839-840
 corticosteroids for, 5:844, 845

Eczema herpeticum as complication of atopic dermatitis, 5:876-877

Eczema vaccination, 5:884
 as complication of atopic dermatitis, 5:876

Edema
 angioneurotic, *see* Angioneurotic edema
 in burns, 4:1198
 cerebral, from meningitis, 4:968-971

acute, in meningococcal meningitis, 4:935
coma and, 4:969
laryngeal, as drug reaction, 5:1112
osmotic treatment of, 4:972
pulmonary, drug therapy, 5:1144, 1244
respiratory disorder and, 4:973-974
tissue, pain of, 5:1174

Effusions
pericardial
in infectious nonspecific pericarditis, 4:137
pericardiosentesis, for relief, 4:174-175, 177
in pericarditis with systemic disease, 4:147, 148, 153-154
relief of cardiac compression, 4:148
ultrasound and, 4:197-204
subdural, in meningitis, 4:906-907, 936-937, 977-978

Electrocardiography, potassium excess in, 5:668

Electroencephalography
for epilepsy, 4:803-804, 805, 807, 811, 814-815
age modification, 6:1183, 1192-1193
examples, 6:1196-1207
recording, 6:1190-1192
rhythms, abnormal, 6:1193-1194
as therapy aid, 6:1194-1195
infantile spasms and, 4:812, 813
petit mal and, 4:808, 809
psychomotor seizures and, 4:806

Electrolytes
baseline requirements for, 5:701
disorders of, *see* Fluid and electrolyte disorders
in infants, 5:688-689
renal function and, 5:626-627

Electronystagmography, 6:602-604, 605

Embolism
arterial, 4:359-361, 412, 414
surgery for, 4:359-361
fat, 5:36
multiple, neuropathy with, 5:1267-1268

Emergencies
allergic, *see* Allergic emergencies
respiratory, 5:924

Emetic treatment
of neuropathies, 5:1240-1241, 1244, 1246, 1247
for poisoning, 4:706

Emphysema, 6:233, 268, 331-345, 354
characteristics of, 6:331-334
chronic obstructive, acidosis from, 5:653
cor pulmonale and, 6:249, 342-343
pulmonary, morphine dosage with, 5:1141
spirometry measures in, 6:234, 238-239
treatment of, 6:334-342, 347, 356

Encephalitis lethargica, 5:284

Encephalomyelitis from immunizations, 5:882-883, 884, 885

Encephalopathies
bilirubin, 4:996-997
hepatic, *see* Hepatic coma
after meningitis, 4:968-972

Endarterectomy of femoral artery, 4:400

Endocarditis, meningococcal disease and, 4:937

Endolymphatic hydrops, *see* Meniere's disease

Endotoxin in septic shock, 4:271, 321-344, 907-909

Endotracheal intubation
in emphysema, 6:336, 341-342
in status asthmaticus, 6:296

Enteric-coated salicylate therapy for pain, 5:1099, 1101

Enteropathy, diabetic, 4:49-51

Epidemiology of noninfectious clinical syndromes, 6:657

Epilepsy
defined, 6:1179-1181
diagnostic procedures in, 6:1190-1215
hyperkinesis in children with, 6:1233-1245
pseudoretardation and, 4:801-818
psychiatric complications of, 6:1247-1261
vertiginous, 6:585-587

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

Epistaxis, 5:55

Eponychium, chronic inflammation of, in diabetic, 4:80

Epsilon aminocaproic acid (EACA) in abruptio placentae with defibrination, 5:411 in primary fibrinolysis, 5:395-396, 398

Erb's palsy from brachial plexus injury, 5:1215

Ergotamine for neuralgia, 5:1275-1276

Erosio interdigitalis blastomycetica, 4:79-80

Erythema anaphylactic, 5:783, 784 in drug allergy, 5:802 infectiosum, polyarthritis with, 6:1149-1150

Estrogen cancer and, 5:564-570 psychologic effects of, 5:587 treatment of menopause with, 5:545-546, 551-562 menopausal osteoporosis, 5:576, 681 with psychiatric treatment, 5:591 vascular disease and, 5:581-586

Ethoheptazine, 5:1144 in treatment of pain, 5:1114

Ethosuximide dosage and preparation of, 6:1228 epilepsy and, 6:1224 side-effects of, 6:1226-1227

Ethylene glycol, poisoning from, 5:646, 653

Etiocolanolone fever, 4:156

Eunuchism, definition of, 5:185

Eunuchoidism, 5:185 hypogonadotropic, 5:149-151

Ewart's sign in acute pericarditis, 4:128

Exchange transfusion in hemolytic disease of newborn, 4:995-996 for poisoning, 4:606-607

Exercise functional, 5:916 therapeutic, 5:913-916 in arthritis, 5:1010, 1012, 1015-1016, 1019, 1021 in cardiac disabilities, 5:937-941 contraindications to, 5:915-916 hydrotherapy as adjunct, 5:915 in low back pain, 5:1028-1035 in peripheral nerve syndromes, 5:999 in respiratory disabilities, 5:928-929 in spinal cord injuries, 5:958-960

for stroke patients, 5:990

Exotoxins in septic shock, 4:321-322

Eyes in alkali poisoning, 4:731 effect of neurosurgery on, 5:1204-1205

Graves' disease and, 6:516-529 neuropathies affecting, 4:48, 62-72, 5:1228, 1232

in Parkinson's disease, 5:310, 316-320 vertigo and, 6:590-591

See also Vision; *specific eye disorders*

Facial neuralgia atypical, 5:1276-1277 surgical relief of, 5:1205

Family, 6:806-820 clergyman's counseling of, 6:891-892 disability and, 5:897-898 of dying patients, 6:751-752 general physician's psychotherapy of, 6:783-789, 806-807, 813-819 poorly adapted, 6:648

Fanconi syndrome magnesium deficiency in, 5:671 potassium deficiency in, 5:666

Farmer's lung, 6:108

Fascioliasis, treatment of, 6:156-157

Fasting effect of, on adipose tissue, 4:1085-1087 in obese children, 4:1157-1158

Fat in diabetic diet, 4:33, 86-87 in glycogen storage disease, 4:1002 in ketotic hypoglycemia, 4:998-999

Fat embolism, 5:36

Fatty acids and blood lipids, 6:1306-1309

Febrile convulsions characteristics of, 6:1182-1185 prophylactic treatment of, 6:1187-1189 treatment of, 6:1185-1186

Feet care of, in arterial disease, 4:354-357 neuropathic pain in, 5:1224-1225, 1231 with deficiency neuropathy, 5:1253, 1259 with diabetic neuropathy, 4:46, 5:1229 with toxic neuropathy, 5:1240 ulcers of, *see* Ulcers, of feet

Femininity index, 5:559

Femoral arteriosclerosis, surgery for, 4:399-400; *see also* Arteriosclerosis, occlusive

Femoral neuropathy, 5:1222-1223
Fetal death and defibrillation, 5:411-415
Fever in drug allergy, 5:804
Fever blister (recurrent labial herpes), 4:556, 558-559, 562-564
Fibrin-stabilizing factor deficiency
diagnosis of, 5:22-23
surgical care in, 5:79
therapy for, 5:52
Fibrinogen deficiency, *see* Afibrinogenemia
Fibrinolysis, primary, 5:384, 395-396
Fibrosis, pulmonary, 6:104, 113
breathing exercises in, 6:112
spirogram patterns in, 6:234
Finger webs, yeast infection of, 4:79-80
Fistula
arteriovenous, 4:409-410
cholecystitis with, 5:522-523
meningitis and, 4:978-979
Flail chest, respiratory failure with, 6:36-37
Fluid and electrolyte disorders, 5:615
in infants, 5:684-687
from acidosis, 5:690-692
from diarrhea, 5:689-690
treatment for, 5:692-697
physiologic basis of, 5:617-624
in pregnancy, 5:714-724
abortion, 5:721-723
hemorrhage, 5:720-721
nausea and vomiting, 5:714-715
surgically induced disturbances, 5:723-724
toxemia, 5:716-720
in surgical patients, 5:699-713
abnormal loss, 5:702-704
in surgical patients, 5:699-713
baseline requirements, 5:699-702
preexisting deficits and excesses, 5:704-709
See also specific disorders
Fluoride ingestion and menopausal osteoporosis, 5:577-578
Focal seizures
focal-motor, 6:1220
drugs effective against, 6:1222-1224
focal-sensory, 6:1220-1221
psychomotor, 6:1221
drugs effective against, 6:1228
Food allergy, 5:775, 776, 852-861
atopic dermatitis and, 5:868
diagnosis of, 5:854-857, 863-864, 868
immunologic characteristics of, 5:853-854
manifestations of, 5:852-853
treatment of, 5:857-861, 868
hyposensitization, 5:859, 868
of urticaria, 5:827-829
Freud, Sigmund, on love and disease, 6:653-654
Friction rub in pericarditis, 4:127, 153-154, 157
Friedreich's ataxia, 5:1003
Frozen shoulder in stroke patients, 5:983, 989
Fructose intolerance, hereditary, 4:1003
Furadantin-induced neuropathy, 5:1238-1239
Gait analysis, 5:895
Gait in Parkinson's disease, 5:264-268, 280
Galactosemia, 4:1003-1005
Gallbladder
agenesis of, 5:501
carcinoma of, gallstones and, 5:497-498, 504
cholesterolosis of, 5:489
empyema of, 5:522
inflammation of, *see* Cholecystitis; Gallstone disease
nonfunctioning, 5:500-504
porcelain, 5:498
rupture of, with bile peritonitis and abscess formation, 5:524-527
Gallstone disease (cholelithiasis)
cause of, 5:480-492
changes in bile in, 5:487-488
incidence of disability from, 5:496
natural history of, 5:493-499
other disorders and, 5:496-498
prevalence of, 5:505
roentgenographic diagnosis of, 5:500-503
silent, *see* Gallstones, silent
surgical treatment of, *see* Cholecystectomy

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

Gallstones
 composition and structure of, 5:480-483
 in cystic duct remnant, 5:536
 formation of, 5:488-490
 incidence of, 5:528
 silent, 5:495, 505-513
 spontaneous disappearance of, 5:494-495
 whether they "get worse," 5:493-495

Ganglion block therapy, 5:1282-1283

Gangrene
 diabetic, 4:102-106, 109-111, 113
 in occlusive arterial disorders, 4:351, 352, 361-367
 in Raynaud's disease, 4:367-368
 vasodilation for, 4:378

Gargoylism, 4:1005-1006

Gasserian ganglion injection for neuralgia, 5:1274

Gastric achlorhydria, vitamin therapy for, 5:1260

Gastrointestinal allergy, 5:775-776, 861-864

Gastrointestinal tract
 absorption of drugs in, 5:1098, 1100, 1138-1139
 in anaphylaxis, 5:783
 bleeding from, 6:179-187
 in diabetic neuropathy, 4:48-51
 disturbance of function of, 5:1174
 effect of morphine on, 5:1139, 1140
 effects of antibiotics on, 5:793
 fluid and electrolyte losses from, in surgical patients, 5:702-703, 706-708
 hypoxia effects on, 6:21
 massive hemorrhage of, 5:1102, 1109, 1118
 occult bleeding of, 5:1101-1102
 postoperative pain in, 5:1174
See also specific parts of gastrointestinal tract

Gastroparesis diabeticorum, 4:48-49

Genetic counseling, 4:844-851; 5:238-239
 in hereditary disorders of blood coagulation, 5:125-133
 in Huntington's disease, 5:342-343

Genetics
 investigation of, 4:837-844
 mental retardation and, 4:837-851
 obesity and, 4:1091-1092, 1100-1104, 1126

Genitourinary tract changes in diabetic neuropathy, 4:51-53

Gentamicin for burn infections, 4:1258-1259

Geriatrics, clergyman's role in, 6:892-893

Giving-up, predisease, 6:645-647, 651-654

Glaucoma, control of pain of, 5:1087

Glomerulonephritis, 6:925
 from immunization, 5:883

Glossopharyngeal neuralgia, 5:1275

Glucose in blood
 cholesterol and, 5:1103
 -6-phosphatase deficiency, 4:1001-1002

Glue sniffing, 6:718

Glycogen storage disease, 4:1001-1002

Glyoxylate
 oxidation of, to oxalate, 4:527-528
 pool of, reduction of, 4:526-527

Goiter
 "iodide," 6:450
 nodular, and cancer, 6:534-549

Gold thioglucose in experimental obesity, 4:1090

Gonadal dysgenesis, 5:218-226

Genococcal arthritis, 6:1130-1139

Gout, 5:1230
 acute, treatment of, 5:1087
 pericarditis and, 4:159
 rehabilitation in, 5:1020-1021
 in renal failure, 6:1045-1046
 drugs in treatment of, 6:1027-1028
 uricemia and, 4:531, 534-535, 536

Grand mal seizures, 6:1217-1218
 drugs effective against, 6:1222-1224

Graves' disease, 6:497-515
 dermopathy of, 6:529-531
 diagnosis of
 LATS, 6:452-453
 triiodothyronine suppression test, 6:453

drug treatment of, 6:504-508
 ophthalmopathy of, 6:516-529
 radioiodine treatment in, 6:499-504, 513-514
 thyroideectomy, 6:497-499
 thyroiditis coexistent with, 6:492

Group therapy, 6:821-841
 in alcoholism, 6:768-772
 "group psychoanalysis," 6:838-839
 how conducted, 6:822-827
 individual psychotherapy compared to, 6:837-838
 practicing physician and, 6:839-840
 therapeutic process in, 6:827-837

Growth
 diseases affecting
 adrenal cortex diseases, 5:168-183
 ovarian diseases, 5:205-217
 pituitary diseases, 5:139-152

testicular diseases, 5:184-204
thyroid diseases, 5:153-167
disorders of, 5:218-240; *see also specific disorders*
thyroid hormone and, 6:460
Growth hormone, fat-mobilizing properties of, 4:1088
Guillain-Barré syndrome, 5:1264-1265
respiratory and airway care in, 5:1265
Gynecological analgesia, *see* Analgesic therapy, for obstetric and gynecologic patients

Hageman trait
diagnosis of, 5:22-23
surgical care in, 5:74-75
therapy for, 5:49-50

Halothane, hepatic reaction following, 6:136, 138, 147

Hamman-Rich syndrome, 6:104, 113

Hand in diagnosis, 6:665-666

Hands in Parkinson's disease, 5:259-261, 279

Handwriting in diagnosis of Parkinson's disease, 5:260

"Hard water" syndrome, 5:673

Hashimoto's thyroiditis, 6:484-492
described, 6:485
perchlorate discharge in, 6:448
plasma thyroid antibodies in, 6:459
treatment of
hormone therapy, 6:490-491
surgery, 6:491-492

Hay fever
antihistamines for, 5:840-841
drug reaction and, 5:1103
urticaria with, 5:830

Head injury, vertigo after, 6:587-590, 609-611

Head pain, surgical relief of, 5:1199, 1200
pain from tumors, 5:1205-1206

Headache
acute, 5:1086
as drug side-effect, 5:1161
migraine, 5:1087, 1117

Hearing, evaluation of, in disability, 5:898

Heart
changes in, in meningitis, 4:973

compression of, in pericardial effusion, 4:148
effect of continuous pain on, 5:1086
in sarcoidosis, 4:151
surgery on, and postpericardiectomy syndrome, 4:170-178
transverse diameter of, in obese, 4:1163

Heart disease
coronary, clergymen and treatment of, 6:895
hand in, 6:666

Heart failure
congestive
azotemia with, 5:631-632
in diabetes, 4:94
digitalis in, 4:94, 148-149, 190-192
in nonspecific pericarditis, 4:136
in obesity, 4:1172-1173
in obstructive pulmonary disease, 6:357
renal failure and, 6:929-930, 942-943, 1053
vertigo from, 6:572, 574-575

Heat, use of, in rehabilitation, 5:909-911

Helplessness, 6:645-654
therapeutic implications of, 6:652

Hemarthrosis, 5:54-55, 85-88

Hematologic reactions to drugs, 5:804

Hematomas, subdural, 4:825-826

Hematuria, therapy for, 5:55-56

Hemiplegics, *see* Stroke patients

Hemochromatosis
associated pericarditis and, 4:159
in diabetes, 4:83

Hemodialysis, *see* Dialysis

Hemolytic anemia
drugs causing, in certain individuals, 5:794-795
gallstones and, 5:496, 497

Hemolytic disease, neonatal, 4:996

Hemolytic reaction to aniline derivatives, 5:1118

Hemophilia
circulating anticoagulants after treatment for, 5:376-379
diagnosis of, 5:22-24
orthopedic management in, 5:84-92

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

psychiatric and social care in, 5:111-124

therapy for, 5:43-48

Hemophilus influenzae, meningitis from, 4:902-904

Hemorrhage
arterial, 4:405-411
gastrointestinal, 4:663-664, 676
massive, 5:1102, 1109, 1118
ocular diabetic, 4:65-66
with vascular neuropathy, 5:1268

Hemosiderosis, idiopathic pulmonary, 6:104

Hemostasis
diagnosis of disorders of, 5:17-37
physiology of, 5:11-17, 94-95
See also Blood coagulation

Henderson-Hasselbach equation, 4:1207; 5:640, 642, 647; 6:317

Henoch-Schönlein purpura, 5:33-35, 449-453, 803, 853

Heparin therapy in fibrillation syndrome, 5:393-394, 398
in abruptio placentae, 5:410-411
hemorrhagic complications, 5:374-376, 394

Hepatic cell dysfunction, gallbladder nonvisualization from, 5:501

Hepatic coma, 6:131-141
diuretic agents and, 6:198
physiologic bases of, 6:131-132
treatment of, 6:132-140, 151

Hepatitis, 6:123-130
alcoholic, 6:168
chronic, 6:122, 125
coma in, 6:136-138, 151
drug-induced, 6:121, 136, 138, 142-152
etiology of, 6:124
fulminant, 6:123-124, 137-140
from phenylpyrazoles, 5:1108
prophylaxis for, 6:125-126
treatment of, 6:121, 126-129

Hepatolenticular degeneration, 4:1039-1042

Hereditary hemorrhagic telangiectasia, 5:444-447

Heroin
for labor pain, 5:1167
as potent analgesic, 5:1138, 1141-1142

Herpes simplex, atopic dermatitis and, 5:876-877

Herpes simplex virus, 4:556, 560

Herpes zoster
neuropathy with, 5:1266

See also Primary herpes with oral ulcers

Herpetic gingivostomatitis, 4:555-561

Herxheimer reaction, 5:793

Hiatus hernia and gallstones, 5:497

Histamine release
nonimmunologic, 5:794
symptoms resulting from, 5:784

Histiocytosis X, pulmonary, treatment of, 6:110-111

Histoplasmosis, 6:1124-1126

History taking, 6:646-647, 656-687
associative technique of, 6:658, 781
illustrations of, 6:681-684
as interviewing, 6:662-663
physician as central figure in, 6:660-661

See also Interviewing

Hives, *see* Urticaria

Hodgkins disease, respiratory failure in, 6:40

Homeostasis, importance of body fluids in, 5:615

Homocystinuria, 4:1031

Hookworm infections, *see* Ankylostomiasis

Hopelessness, 6:645-654
therapeutic implications of, 6:652

Hormonal therapy
ACTH, *see* Adrenocorticotrophic hormone therapy
psychologic effects of, 5:587, 593-594
treatment of menopause by, 5:550-563
menopausal osteoporosis, 5:576, 681
objections to, 5:545-548
with psychiatric treatment, 5:590-595
regulation of dosage, 5:554-559

Horner's syndrome in bronchial plexus injury, 5:1216

Horse serum antitoxin, 5:786, 807-808

Huntington's disease
classification of, 5:333
diagnosis in, 5:332, 346-347
genetic counseling for, 5:342-343
prevalence of, 5:334
prognosis in, 5:350
psychiatric treatment of, 5:344-345
reproductive control in, 5:344-345
surgical therapy in, 5:340
treatment of, 5:256, 332-350

Hydatidiform mole, hyperthyroidism with, 6:513

Hydralazine-induced neuropathy, 5:1239

Cumulative Index / 1385

Hydration in reduction of airway obstruction, 4:1173

Hydrocephalus, 4:819-825
meningococcal disease and, 4:937, 982

Hydrogen ions
in acid-base regulatory system, 5:636-638
types of derangements, 5:641-642

metabolic alkalosis from loss of, 5:655-656, 659-660

Hydrotherapy as adjunct to therapeutic exercise, 5:915

Hydroxypyruvateuria, 4:1034

Hymenoptera sensitivity, *see* Insect sting reactions

Hyperaldosteronism, *see* Aldosteronism

Hyperbilirubinemia, neonatal, 4:995-997

Hypercalcemia
calcium stones and, 4:468-469
due to metastatic carcinoma and myeloma, 5:681-682

hyperparathyroidism and, 4:489, 1010; 5:682-683

idiopathic infantile, 4:1007-1008

magnesium deficiency with, 5:670-671

Hypercalciuria
calcium stones and, 4:468-470

idiopathic, 4:469; 5:680

Hypercapnia, 6:239
in status asthmaticus, 6:317-319

treatment of, 5:654

Hyperglycemia
in human obesity, 4:1093

in meningitis, 4:974-975

mental retardation associated with, 4:1029

Hyperinsulinemia in obesity, 4:1093

Hyperkalemia in renal failure, 6:940, 1040-1042

Hyperkinesis
drug therapy and, 6:1236-1249

etiology of, 6:1233-1234

parent counseling, 6:1244-1245

symptom complexes associated with, 6:1234-1236

teacher counseling, remedial education and psychotherapy, 6:1245

Hyperlipidemia
dietary treatment of, 6:1328-1340

drug treatment of, 6:1341-1350

mechanisms involved in, 6:1313-1325

Hyperlipoproteinemia, type I, 6:1317-1319, 1332-1333

Hyperlipoproteinemia, type II, 6:1319-1321, 1333-1334

Hyperlipoproteinemia, type III, 6:1321-1322, 1334-1336

Hyperlipoproteinemia, type IV, 6:1322-1323, 1334-1336

Hyperlipoproteinemia, type V, 6:1323-1324, 1334-1336

Hypernatremia, 4:1042-1043

Hyperoxemia in cor pulmonale, 6:255, 259-260

Hyperparathyroidism
calcium stones and, 4:468-469, 497

diagnosis of, 4:489-499

hypercalcemia and, 5:682-683

magnesium deficiency with, 5:671

surgical treatment of, 4:489-492

See also Kidney stones

Hyperpernia in poisoning, 4:652

Hyperplasia, adrenal, congenital, 5:168-174

Hyperpotassemia, 5:667-669
treatment for, 5:668-669

Hyperpyrexia, 4:664

Hypertension
arterial, 5:1279

cranial, from poisoning, 4:611, 614

in diabetes, 4:37-38, 87, 93

in obese patients, 4:1143-1144

pulmonary, in cor pulmonale, 6:251-254

in renal failure, 6:1050-1052

vertigo from, 6:572

Hypertensive cardiovascular disease
and artificial kidney, 6:1062-1063

Hypertensive cerebral hemorrhage
symptoms of, 5:974

See also Stroke patients

Hyperthermia in meningitis, 4:974

Hyperthyroidism, 5:163-166
hand in, 6:665

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

See also Graves' disease; Plummer's disease

Hyperuricemia, 4:1036-1037

Hypervalinemia, 4:1029-1030

Hypnotic drugs, 5:1116, 1119

Hypocalcemia

- mental retardation and, 4:1010-1011
- renal tubular acidosis and, 4:515-516, 517
- transfusion-induced, 5:381-382

See also Hypoparathyroidism; Uremia

Hypoglycemia

- with glycogen disease, 4:1001-1003
- idiopathic, spontaneous, 4:999-1001
- in infants of diabetic mothers, 4:993-994
- with ketosis, 4:998-999
- leucine-sensitive, 4:997-998
- as metabolic neuropathy, 5:1230
- in neonatal period, 4:988, 991-994
- nocturnal, 4:17
- obesity and, 4:1128
- prevention of, in cerebral vascular disease, 4:100
- as secondary to steroid therapy, 4:19
- from sulfonylurea therapy, combined with insulin, 4:22

Hypogonadism, 5:185-186

Hypokalemia

- after amphotericin B therapy, 4:953
- renal tubular acidosis and, 4:515-516

Hypolipemic drugs, 6:1310-1311

Hyponatremia

- meningitis and, 4:975
- mental retardation and, 4:1043
- in poisoning, 4:652
- in renal failure, 6:1040

Hypoparathyroidism

- chronic idiopathic, 4:1008-1010
- idiopathic, 5:230-237
- treatment of, 5:678-678

Hypophosphatasia, 4:1042

Hypophysectomy in Graves' ophthalmopathy, 6:521

Hypopituitarism, 4:1046

Hypopituitary dwarfism, 5:145-149

Hyposensitization

- to insect sting reactions, 5:799, 815, 818-820
- in urticaria, 5:833

Hypotension

- anaphylactic, 5:783, 784-785
- treatment, 5:787-788, 817-818
- meningitis and, 4:973
- orthostatic in diabetic neuropathy, 4:57-58
- renal failure and, 6:929-930

Hypothalamic-pituitary axis, damage to, from meningitis, 4:981

Hypothalamus

- lesions of, in childhood obesity, 4:1152
- pleasure-giving center in, 4:1117-1118
- punishment pain system in, 4:1118
- satiety center of, 4:1117
- TSH regulation by, 6:451

Hypothermia and intravenous injections, 5:1157

Hypothyroidism, 5:155-163

- cholesterol level in, 6:460
- diagnostic test in, 6:451-452
- hand in, 6:665
- in infancy and childhood, 4:1151-1152
- iodide-organification defect and, 6:448
- low basal metabolism and, 4:1127
- from radioiodine treatment, 6:500-502
- treatment of, 6:465-473

Hypovolemia, 4:285-288, 291-293

Hypoxia, 6:12-13, 15-25, 239, 240, 244, 350

- arterial, with obesity, 4:1162-1163
- defining extent of, 6:22-25
- signs and effects of, 6:18-22

Hysterectomy in abruptio placentae, 5:409

Illness

- denial of, 6:721, 722-723
- feelings of loneliness in, 6:889-892
- felt to be punishment, 6:887-889
- psychological disturbances in, 6:732-745, 866-869

See also Disease

Immunity problems of kidney transplantation, 6:952-964

Immunizations, 5:879-880

- allergic and immunologic reactions to, 5:881-883
- direct induction of disease by, 5:881
- in pregnancy, 5:881
- reactions to individual vaccines, 5:883-889

Impotence in diabetic, 4:54-55

Indandione, hemorrhagic complications from, 5:372-374

Indometacin therapy for pain, 5:1110

Infantile spasms, 6:1218

Infants

- body water in amount, 5:617, 684-685

requirements, 5:685-688
 fluid and electrolyte disturbances in, 5:684-697
See also Newborn

Infarction, myocardial, *see* Myocardial infarction

Infection
 acute, in febrile convulsions, 6:1186
 airway obstruction and, 4:1173
 burn wounds, control of, 4:1275-1277
 urticaria with, 5:830

Inflammatory neuropathies, 5:1263-1266

INH, *see* Isoniazid

Injury, traumatic, *see* Traumatic injury

Insect sting reactions, 5:814-824
 characteristics of, 5:814-816
 urticaria, 5:815, 830
 fatalities from, 5:814, 815-816
 hyposensitization against, 5:790, 815, 818-820
 patient's education in cases of, 5:815, 821-822
 treatment of, 5:816-818, 822-823

Insecticide as poison, 4:626-632

Inspection, 6:665-666

Insulin
 daily secretion of, by pancreatic beta cells, 4:16
 human, 4:18-19
 idiopathic chronic resistance to, 4:16-24, 87
 lipodystrophy and, 4:83
 in obese diabetic, 4:1190
 pork, 4:18
 requirement for, in diabetic with infection, 4:27
 sensitivity to, of adipose tissue, 4:1086

Insulinoma, 4:1001

Intensive care units, psychotic reactions to, 6:743

Intermediate-acting block therapy, 5:1185

Intermittent positive-pressure breathing (I.P.P.B.), 6:92-102, 351
 aerosol with, 6:366, 368
 in emphysema, 6:335-339, 341-342
 in status asthmaticus, 6:311-317

Interstitial fluids, 5:620-621

Intertrigo, candida, 4:80-81

Interviewing, 6:656-687, 778-781
 focusing verbal exchange in, 6:677-679

goals of, in initial interview, 6:672-673

indiscretions in, 6:674-677

inspection in, 6:665-666

process of, 6:667-674

subsequent, 6:679-681
See also History taking

Intracranial pressure increased
 in pyogenic meningitis, 4:900-901, 924-925
 in tuberculous meningitis, 4:944-945

Intracranial surgery for neuralgia, 5:1274-1275

Intrathecal therapy
 in meningococcal meningitis, 4:935-936
 in neonatal meningitis, 4:914
 in pyogenic meningitis, 4:927-928

Intravenous route for postoperative patient, 5:1157-1158

Ischemia, 4:350-351, 386, 387, 388
 with neuritis, 4:358, 387
 splanchnic, regional-block therapy for, 5:1182
 with ulceration, 4:377-378

Ischemic neuropathies, *see* Vascular neuropathies

Islet cell adenoma, 4:1001

Isoniazid, 5:850
 desensitization to, 5:809

Isoniazid-induced neuropathy, 5:1237-1238
 INH withdrawal in, 5:1238

Isoniazid therapy
 in children, 4:183, 184, 187
 for drug-induced neuropathy, 5:1239
 for tuberculous meningitis, 4:939, 941-942, 949
 for tuberculous pericarditis, 4:143

Isoproterenol
 for arterial disorders of the extremities, 4:385
 for pyogenic meningitis, 4:903-909
 for shock, 4:243, 246, 250, 252, 271, 274, 283, 284-285, 291, 314-315, 327, 337

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

Jaundice in drug allergy, 5:805
 Jewish patients, 6:893-894
 Joints
 contractures of, 5:907
 degenerative disease of, 5:1019-1020
 measurement of mobility of, 5:895
 in stroke patient, 5:978, 980
 in peripheral nerve syndromes, 5:998-999
 protection of, in neuropathic patient, 5:1213

Karyotype, genetic, 4:838, 839
 Ketonuria as drug reaction, 5:1103
 Kidney stones
 analysis of, 4:466, 477-479
 calcium, 4:467-470
 hyperparathyroidism and, 4:489-492, 497
 treatment, 4:472, 480-481, 483-485, 494-501, 526
 causes of, 4:512
 cystine, 4:470, 473, 539, 540, 543, 545-548
 treatment, 4:473, 540, 543, 545-548, 551
See also Cystinuria
 diagnosis of, 4:465-471, 477-479
 hypercalcemia and, 4:468-469
 hypercalciuria and, 4:468-470
 hyperparathyroidism and, 4:489-492, 497
 idiopathic, 4:500-502
 with infection, 4:497, 502-503, 505-512
 prognosis, 4:513
 lithiasis and, *see* Lithiasis, renal
 matrix, 4:465, 471, 494-495
 mixtures of, 4:473
 oxalate, 4:522-529; *see also* Oxaluria
 recurrence of, 4:464, 496, 501-503
 renal tubular acidosis and, 4:519
 treatment of
 aims, 4:473-474
 allopurinol, 4:532-536
 oxalate reduction, 4:526-529
 penicillamine, 4:543-547
 phosphates (inorganic), 4:494-503
 special diet, 4:480-481, 482, 483-485
 triple-phosphate, 4:505-514
 uric-acid, 4:470, 472-473, 531-536
 xanthine, 4:471, 536-537

Kidneys
 in acid-base regulatory system, 5:638-639, 650
 acidosis from, 5:642
 artificial, 5:626; 6:923

types, 6:1057-1058
See also Dialysis
 effect of continuous pain of, 5:1086
 hypoxia effects on, 6:21-22
 morphine distribution to, 5:1139
 relief of pain in, 5:1204
 solitary, renal failure and, 5:933
 transplantation of, 5:626; 6:923, 952-953
See also Nephrotic syndromes; Renal disease; Renal failure; Uremia
 Kwashiokor, 4:1029, 1036
 Kyphoscoliosis, respiratory failure with, 6:38-39, 112

Labial herpes, recurrent, 4:556, 558-559, 562-564

Labor
 analgesic effect on course of, 5:1169
 prevention of dehydration in, 5:720

Labor pain
 analgesia for, 5:1165-1171
 control of, 5:1088, 1095
 as function of attitude, 5:1165-1166

Labyrinth and paroxysmal vertigo, 6:1293-1295

Lactic acidemia, 6:270-271

Lactic acidosis, 5:644-645
 treatment of, 5:651

Laparotomy, respiratory failure after, 6:36-37

Laryngeotracheobronchitis, 6:366

Larynx, obstruction of
 anaphylactic, 5:787, 789
 as complication of bleeding, 5:56

Lateral femoral cutaneous neuropathy, 5:1223

Laurence-Moon-Biedl syndrome in childhood obesity, 4:1152-1153

Lavage, gastric, 4:602-605
 for poisoning, 4:628, 631, 637, 638, 674-675, 704-706

Lead as poison, 4:710-728

Lead neuropathy, 5:1242-1243
 prevention of, 5:1243

Leg pain
 neuropathic, 5:1223, 1224, 1227
 regional-block therapy for, 5:1183

Leishmaniasis, visceral, 6:155-156

Leprosy
 cutaneous anesthesia in, 5:1086
 neuropathy with, 5:1266

Leukemia
 pulmonary insufficiency in, 6:111
 thrombocytopenia with, 5:435-436

Levallophan, 5:1146, 1149-1150
 for labor pain, 5:1168

Levarterenol in shock, 4:250-251, 306
 Levorphanol, 5:1146
 Light urticaria, 5:834
 Lipid metabolism, disorders of, 4:1011
 mental retardation with, 4:1012-1018
 neuropathies, 5:1211, 1232-1233
 Lipoproteins, 6:1313-1316
 major classes of, 6:1329-1332
 Lithiasis, renal
 causes of, 4:512
 with hyperparathyroidism, 4:497
 with infection, 4:505-514
 See also Kidney stones
 Liver
 barbiturate action on, 4:683
 damaged, morphine dosage with, 5:1141
 drug metabolism in, 5:1139, 1142, 1148
 effect of salicylates on, 5:1103
 homotransplantation of, 6:140
 Liver diseases
 bleeding in, 5:368-371
 cirrhosis, primary biliary, 6:1355-1357
 in drug allergy, 5:805
 gallstone formation and, 5:488
 hereditary and neonatal, 6:1352-1354
 lack of information about, 6:110
 miscellaneous forms of, 6:1357-1358
 obstructive, 6:1325, 1354-1355
 parasite, 6:121, 153-164
 See also specific diseases
 Loeffler's syndrome, 6:105-106
 Long-acting block therapy, 5:1185-1191
 background of, 5:1185-1186
 intrathecal use of, 5:1188-1191
 managing complications of, 5:1186
 peripheral use of, 5:1186-1188
 Long thoracic neuropathy, 5:1217
 Love and disease, 6:654
 Low back pain, 5:1022-1035
 mechanics of, 5:1022-1028
 treatment of, 5:1028-1035
 Lower extremity neuropathies, 5:1221-1225
 Lower plexus root injury neuropathy, 5:1215-1216

LSD, 6:715-716, 742, 804
 Lues and associated pericarditis, 4:151
 Lumbar puncture, 4:880-881, 981-982
 Lumbrosacral serves in regional-block therapy, 5:1180-1181
 Lungs
 edema of, 6:42
 aerosol therapy for, 6:370
 renal failure and, 6:942-943
 fluid therapy and, 4:1278
 radiation damage of, treatment of, 6:110
 surgical extirpation of, 6:42
 cor pulmonale and, 6:251
 tests of function of, 6:233-239
 in cor pulmonale, 6:257-258
 See also Ventilation; *specific diseases, entries beginning with Respiratory*
 Lupus erythematosis (LE), 5:379, 432
 arthritis with, 5:1011
 disseminated, and associated pericarditis, 4:155
 drug-induced, 5:805
 respiratory ventilatory impairment in, 6:104
 urticaria with, 5:830
 Lupus nephrotic syndrome, 6:1008-1009
 Lymphadenitis
 antibiotic therapy in, 6:391-395
 endolymphatic therapy in, 6:379
 Lymphangiosarcoma, treatment of, 6:418-419
 Lymphangitic carcinoma, 6:111
 Lymphedema, 6:373-421
 classification of, 6:373, 375-376, 398-400
 lymphangiographic evaluation in, 6:373, 375-379
 treatment of
 endolymphatic therapy, 6:379
 of idiopathic lymphedema, 6:381-383
 of postmastectomy lymphedema, 6:396-412
 of secondary lymphedema, 6:384-390
 surgical treatment, 6:413-418
 Lymphoma, treatment of, 6:111

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

Macroglobulinemia, 5:35, 455-458

Magnesium

- basic considerations for, 5:669-670
- deficiency of, 5:670-672
- excess of, 5:672-674
- potassium and, 5:663

Main's syndrome, 6:721, 724-727

Malignant tumors, surgical treatment of, 5:1202-1203

- head tumors, 5:1205-1206

Malnutrition and pseudore retardation, 4:758-758

Manic depressive psychosis, lithium carbohydrate in, 6:804

Mannitol

- in burn therapy, 4:1224
- for shock, 4:268-269, 293

Maple syrup urine disease, 4:1030

Marfan's syndrome, hand in, 6:666

Marijuana, 6:715, 805

Massage, 5:912-913

Mastectomy, lymphedema after, 6:396-412

Mastocytosis, systemic, 5:784

Matrix kidney stones, 4:471, 494-495

Maturation, delayed, and mental retardation, 4:754

Maturation index, 5:559

Maximal voluntary ventilation test, 6:235-236

Measles vaccine, complications from, 5:885-886

Medial plantar neuropathy, 5:1224

Median neuropathy, 5:1220-1221, 1234

"Medic-Alert" identification, 5:790, 809-810

Medication for postoperative patient choice of, 5:1160-1162

- dosage of, patient's age and, 5:1159-1160
- evaluation of patient before, 5:1156-1157
- route of admission of, 5:1157-1158
- timing of, 5:1158

See also Analgesic therapy, for postoperative pain

Mediterranean fever, 4:156

Medulla, effect of morphine on, 5:1139

Mefenamic acid therapy for pain, 5:109-1110

Meiosis, 4:838, 841

Meniere's disease, 6:553-567, 605-606

Meninges, involvement of, by cancer, 4:854

Meningitis

- acromegaly after treatment of, 4:168
- acute syphilitic, 4:894
- autonomic changes in, 4:972-974

brain abscess and, 4:978

cardiac changes in, 4:973

cerebral edema in, 4:935, 968-971

CSF in, 4:879-896, 976

convulsions and, 4:901, 902, 943-944, 971-972

cryptococcus, 4:886, 894

- amphotericin B therapy, 4:956, 957, 958

fistula and, 4:978-979

focal neurologic dysfunction and, 4:979-982

gastrointestinal changes in, 4:974

hyperglycemia in, 4:974-975

hyperthermia in, 4:974

meningococcal, 4:929-938

metabolic disturbances in, 4:975

mycotic, 4:951-960

neonatal, 4:909-915

overhydration in, 4:975

peripheral vascular collapse in, 4:973

purulent, 4:885, 887, 891-893

pyogenic

- in adults, 4:918-928, 946, 963
- in infants and children, 4:898-915
- respiratory disorder in, 4:973-974
- sequelae of, 4:968-983
- subdural effusion and, 4:906-907, 977-978
- tuberculous, 4:939-950
- viral, 4:961-967

Meningococcal infection, 4:929-938

- clinical types of, 4:930-931
- See also specific infections*

Meningococcemia, chronic, 4:931

Menopause

- atherosclerosis and, 5:581-586
- psychodynamics of, 5:588-590
- symptoms of, 5:546-548
- treatment of, 5:545-563
- by hormonal therapy, 5:545-546, 550-562, 590-595
- by nonhormonal therapy, 5:550
- by psychiatric therapy, 5:554, 561, 587-595

See also Osteoporosis—menopausal

Menorrhagia, hemorrhagic defects and, 5:57-58

Menstrual cycle, behavior patterns and, 6:850

Meperidine (Demerol), 5:1143-1145

- dependence on, 5:1128, 1132, 1176
- for treatment of pain
- labor pain, 5:1166-1167, 1168, 1171

postoperative pain, 5:1154

Mephentermine for shock, 4:243, 246, 250, 295, 304, 315

Mephobarital
 dosage and preparation of, 6:1228
 epilepsy and, 6:1223
 side-effects of, 6:1226-1227

Mercury neuropathy, 5:1246

Mercury as poison, 4:734-739

Mescaline, 6:715, 742, 804-805

Mesencephalic tractotomy to relieve pain, 5:1201

Metabolic neuropathies, 5:1226-1235

Metachromatic leucodystrophy, 5:1233

Metaraminol for shock, 4:249-251, 290, 306-307

Methadone, 5:1148-1149
 drug dependence and, 5:1132, 1133
 for postoperative pain, 5:1176

Methemoglobinemia
 hereditary, 4:1043-1044
 from phenacetin, 5:1105

Methionine malabsorption, 4:1033

Methotripteneprazine therapy for pain
 labor pain, 5:1169, 1171
 postoperative pain, 5:1176
 postpartum pain, 5:1173

Methoxamine for shock, 4:246, 251-252, 294, 306

Methsuximide
 dosage and preparation of, 6:1228
 epilepsy and, 6:1225
 side-effects of, 6:1226-1227

Methyl alcohol (Methanol) poisoning, 5:646, 652

Methyl cellulose for appetite reduction, 4:1141-1142

Methysergide for neuralgia, 5:1276

Micelles, 5:484-487

Middle ear and paroxysmal vertigo, 6:1292-1293

Migrain, vertigo in, 6:591-593

Migrainous neuralgia, 5:1275-1276

Milestones in life and changes in health, 6:647-649

Ministers, assistance to physician by, 6:885-899

Minot-von Willebrand syndrome, prolonged bleeding with, 5:1102

Miosis from morphine, 5:1140

Mipafox neuropathy, 5:1245-1246
 symptomatic and preventive treatment of, 5:1245-1246

Mitosis, 4:838

Monoamine oxidase inhibitors, in Parkinson's disease, 5:293, 297-298

Mononeuropathy, metabolic, 5:1228-1229, 1234

Mononucleosis, infectious
 arthralgia with, 6:1149
 with pericarditis, 4:151

Morphinan derivatives, 5:1145-1146

Morphine, 5:1137-1141
 absorption, dosage and metabolism of, 5:1138-1139
 activity and structure relationships of, 5:1137-1138
 contraindicated in burn patients, 4:1198
 dependence on, 5:1123, 1128-1129
 for labor pain, 5:1167, 1171
 mechanism of analgesia and addiction to, 5:1139
 pharmacologic actions of, 5:1139-1141
 for postoperative pain, 5:1156, 1159, 1160-1161
 of gynecologic patients, 5:1175-1177
 tolerance toward, 5:1141

Morquio's syndrome, 5:237-238

Mosaicism, 4:841

"Mourning," 5:896

Mucopolysaccharidosis, 4:1005-1006

Multiple sclerosis, vertigo from, 6:579-585

Mumps
 arthritis in, 6:1147
 vaccine, complications from, 5:886

"Munchausen's Syndrome," 6:705

Muscle relaxants in treatment of pain, 5:1114-1116, 1119

Muscles
 atrophy of, 5:906-907
 hypoxia effects on, 6:21
 in neuropathy
 Bell's palsy, 5:1280-1281, 1283
 effect of neuropathy, 5:1218, 1217, 1220-1223, 1229, 1240, 1244, 1245, 1253
 muscle-training exercises, 5:1237
 in peripheral nerve syndromes, 5:998-999

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

- skeletal, morphine distribution to, 5:1139
- testing of strength of, 5:895-896
 - in stroke patients, 5:977-978
- Muscular dystrophy**
 - respiratory failure in, 6:33
 - See also Dystrophy*
- Mussel neuropathy, 5:1247**
- Myalgia, treatment of pain of, 5:1095**
- Myasthenia gravis**
 - acidosis from, 5:653
 - respiratory failure in, 6:33, 34
- Mycotic arthritis, 6:1124-1128**
- Mydriasis from meperidine, 5:1144**
- Myeloma, multiple, mypercalcemia due to, 5:682**
- Myelopathy, *see* Spinal cord injuries**
- Myeloproliferative syndromes, bleeding complications in, 5:380-381**
- Myocardial infarction**
 - acute
 - differentiated from acute pericarditis, 4:147-148
 - pericarditis of, 4:176-179
 - shock and, 4:299-318
 - meperidine for, 5:1144
 - treatment of pain of, 5:1095
 - vertigo from, 6:572
- Myocarditis for immunization, 5:884**
- Myocardium, emetine effect on, 4:151**
- Myoclonic seizures, 6:1219-1220**
- Myopathic-myasthenic syndrome, neuropathy with, 5:1271**
- Myopathies**
 - inflammatory, 5:1045
 - primary, definition of, 5:1036
 - rehabilitative goals in, 5:1037
- Myxedema**
 - causing cholesterol pericarditis, 4:158
 - coma, 6:468-469
 - with drug-induced neuropathy, 5:1240
 - median neuropathy with, 5:1220
 - as metabolic neuropathy, 5:1232
- Nalorphine, 5:1138, 1149**
- Narcolepsy, 6:1263-1264**
 - associated symptoms, treatment of, 6:1271-1272
 - in children, treatment of, 6:1272
 - decreased wakefulness, treatment of, 6:1264-1267
 - limitations, 6:1272-1273
 - nocturnal sleep, inadequate, treatment of, 6:1268
 - pupilogram, 6:1269-1271
- Narcotic addiction, 6:711-713**
 - See also Drug addiction*
- Narcotic analgesic therapy for pain**
 - analgesic combinations, 5:1119, 1129
 - labor pain, 5:1166-1168
 - neuropathic pain, 5:1239
 - postoperative pain, 5:1158, 1175
 - "weak" drugs, 5:1110-1114
- See also Opiate dependence; Opiates*
- Narcotic antagonists, 5:1149-1150**
- Nasal occlusion, antihistamines for, 5:840-841, 842**
- Neck**
 - burns of, 4:1311
 - pain of, 5:1183, 1200
 - rigidity of, in Parkinson's disease, 5:262-263, 279-280
- Necrobiosis lipodica, 4:73-74**
- Necrosis**
 - cortical, in meningitis, 4:979
 - of feet, in diabetes, 4:109-113
 - renal papillary, in diabetic, 4:41
- Neoplasms associated with pericarditis, 4:159-160**
- Neoplastic (carcinomatous) neuro-mopathies, 5:1270-1271**
- Nephritis**
 - from immunization, 5:884
 - "phenacetin," 5:1106
- Nephropathy**
 - analgesic, 5:1118, 1119
 - diabetic
 - diagnostic tests, 4:39-40
 - hypophyseal stalk section, 4:41
 - pathology, 4:31-32
 - prognosis, 4:42
 - renal arteriosclerosis, 4:142
 - renal biopsy, 4:31
 - renal papillary necrosis and, 4:41
 - sulphonylurea drugs, 4:31
 - treatment, 4:31-42
 - nonspecific, from phenacetin, 5:1106
- See also Renal failure*
- Nephrotic syndromes**
 - idiopathic, 6:1000-1008
 - lupus, 6:1008-1009
- Nerve decompression in Bell's palsy, 5:1282**
- Nerve fiber transmission of pain, 5:1084-1085**
- Nervous system, *see* Central nervous system; Degenerative neurologic disease; Peripheral nerve syndromes; specific nervous disorders**
- Neuralgia, 5:1272-1277**
 - defined, 5:1211-1212

regional-block therapy for, 5:1184, 1185, 1274
specific therapy for, 5:1088
surgical therapy for, 5:1273-1274
 neuralgia of head and neck, 5:1204-1205
 secondary neuralgia, 5:1204

Neuritis
 defined, 5:1211
 See also Neuropathies; Polyneuritis

Neurogenic vesical dysfunction, 4:52-54

Neurolytic drugs, *see* Regional-block therapy

Neuroma
 acoustic, vertigo and, 6:576-579, 613
 surgical therapy for, 5:1203-1204, 1224
 from surgery, 5:1199

Neuropathies
 case histories of, 5:1218-1222, 1224, 1257
 general care of, 5:1212-1214
 surgical treatment of, 5:1216, 1220, 1223, 1224, 1225, 1232, 1273-1275
 varieties of, 5:1215-1284; *see also* specific neuropathies
 See also Neuralgia; Neuritis

Neurophysiology, 5:1197-1199
 modality-specific, 5:1197-1198
 of structures in emotional response, 5:1198-1199

Neurosis
 differential diagnosis between psychosis and, 6:877-879
 sociopathy compared to, 6:709

Neurosurgical therapy, 5:1197-1208
 for Bell's palsy, 5:1282-1283
 for head and neck pain, 5:1204-1206
 for neuropathies, 5:1216, 1220, 1223, 1224, 1225, 1232, 1273-1275
 procedures for, 5:1199-1204

Newborn
 decreased conjugation of bilirubin in, 4:996-997
 of diabetic mother, 4:993-994
 effect of analgesics on, 5:1144, 1169-1170
 exchange transfusion for, 4:995, 996
 hemolytic disease of, 4:996

hyperbilirubinemia in, 4:995-997
meningitis in, 4:909-915
metabolic and endocrine disorders in, 4:988-997
 See also Infants

Nicotinamide therapy for deficiency neuropathy, 5:1255-1257

Nitrofurantoin-(furadantin) induced neuropathy, 5:1238-1239

Nitrogen mustard in therapy for chronic insulin resistance, 4:23

Nocardiosis, 6:1124-1128

Normosol-R for burn therapy, 4:1221, 1222, 1224

Nutmeg, 6:715, 742

Nystagmus, vertigo and, 6:580, 599-601, 603

Obesity
 acidosis from, 5:653
 adipose tissue metabolism and, 4:1083-1094
 in adolescence, 4:1116-1117
 anthropologic characteristics in, 4:1105-1106
 appetite suppressants in, 4:1172
 cardiopulmonary disorders in, 4:1162-1179
 cardiopulmonary syndrome of, 4:1164-1165
 cardiorespiratory function in, 4:1162-1163
 CNS in relationship to development of, 4:1117-1119
 in childhood, 4:1116, 1146-1160
 criteria for, 4:1097
 height-weight tables, 4:1107
 table of standards, 4:1098, 1099
 definition of, 4:1083, 1096
 diabetes and, 4:1181-1190
 basic therapy, 4:90, 1181-1190
 diabetes mellitus and, 4:1106-1107
 diagnosis of, 4:1127-1129
 dietary treatment of, 4:1125-1163
 drug therapy in, 4:1138-1144
 evaluation of patient with, 4:1131-1132
 experimental, 4:1090-1092
 frequency of, 4:1098-1100

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

gallbladder disease and, 5:496, 497
 general principles of treatment of, 4:1129
 genetic, 4:1126
 difficulties in estimating genetic parameters, 4:1100
 in experimental animals, 4:1091-1092, 1100, 1101
 familial aggregation, 4:1101-1102
 racial or ethnic comparisons, 4:1103-1104
 sex ratios, 4:1104-1105
 twin studies, 4:1102-1103
 hypoglycemia and, 4:1128
 hypothyroidism and, 4:1127
 incidence of, and behavior abnormality in, 4:1112-1113
 measurement of triceps skinfold thickness in, 4:1097-1098, 1107
 metabolic abnormalities in, 4:1093-1094, 1126
 overweight condition vs., 4:1096-1097, 1147
 pathophysiology of, 4:1165-1168
 physical activity and, 4:1127
 problems in treatment of, 4:1120-1122
 psychiatric aspects of, 4:1111-1123
 from reduced caloric expenditure, 4:1126-1127
 regulatory, 4:1128
 relationship of, to addiction, 4:1119-1120
 respiratory failure in, 6:34-35, 102
 schizophrenia and, 4:1113-1116
 steroids causing, 4:1126
 tumors affecting food-control center in, 4:1126, 1128
 Obstetric analgesia, *see* Analgesic therapy—for obstetric and gynecologic patients
 "Obstetric shock," 5:407
 Obstructive disease, *see* Respiratory failure—obstructive
 Occlusion
 arterial
 acute, 4:411-415
 vasodilators for, 4:370-371, 375, 376-378
 See also Arteriosclerosis, occlusive
 vascular, neuropathy with, 5:1267-1268
 Occlusive dressings in burn wounds, 4:1251-1253
 Older persons, clergymen and needs of, 6:892-893
 Oliguria in shock, 4:294, 296-297

Opiate dependence
 narcotic antagonists and, 5:1149
 relief of pain and, 5:1121-1135
 Opiates, varieties of, 5:1136-1143; *see also* specific opiates
 Opioids, varieties of, 5:1143-1149
 Oral contraceptives, suppression of dysmenorrhea by, 5:587
 Oral hypoglycemic drugs in obese diabetic, 4:1187-1190
 Orthopedic management in hereditary disorders of blood coagulation, 5:84-92
 Orthoses, 5:901-902
 definition of, 5:900
 Osteitis fibrosa cystica, 6:1048
 Osteoarthritic knee, rehabilitation of, 5:1020
 Osteogenesis imperfecta, 5:32, 447-448
 Osteomalacia, 6:1048
 renal tubular acidosis and, 4:519
 Osteomyelitis
 from immunization, 5:884
 septic arthritis in children with, 6:1111-1112, 1112-1113
 Osteoporosis
 corticosteroids and, 5:849
 from disuse, 5:907
 menopausal
 defined, 5:571
 described, 5:680-681
 evaluation of, 5:571-573, 578-579
 theory of hormone deficiency, 5:573-576
 treatment, 5:548, 553-554, 571-580, 681
 in primary biliary cirrhosis, 6:212
 Otorrhea and meningitis, 4:978
 Ovaries, growth-affecting diseases of, 5:205-217
 Oxalate
 in kidney stones, 4:522-529
 metabolism of, 4:524-525
 reduction of, 4:526-528
 Oxaluria, 4:522-529
 Oxidation-reduction metabolic disorder, 4:1043-1044
 Oxygen, consumption of, in obesity, 4:1163
 Oxygen therapy
 for burns, 4:1270-1272
 for hypoxia, 4:1171-1172; *see also* Hypoxia
 for obesity, 4:1171-1172
 Oxymorphine, 5:1138, 1142
 for postoperative pain, 5:1142, 1176
 Oxyphenbutazone therapy for pain, 5:1108-1109

Pain, 5:1083-1210
 analgesic therapy for, 5:1094-1153, 1164-1179
 in arteriosclerosis obliterans, 4:95
 from burns, relief of, 4:1197-1198
 clinical aspects and necessity for relief of, 5:1086
 concepts of, 5:1083-1085
 control of, 5:1086-1091
 cancer patient's pain, 5:1089-1091, 1125
 in coronary artery disease with diabetes, 4:97
 nonsurgical therapy for, 5:1197-1208
 opiate dependence and, *see* Opiate dependence—relief of pain and perception of, 5:1084-1085, 1199
 regional-block therapy for, 5:1180-1196
 rest, in occlusive arterial disease, 4:113
See also specific types of pain
 Pain-prone individuals
 as addicts, 5:1125-1126
 management of, 5:1128
 recognition of, 5:1127
 Palsy
 Bell's, *see* Bell's palsy
 from brachial plexus injury, 5:1215
 facial and meningitis, 4:979-980
 "Saturday Night," 5:1217-1218
 with toxic neuropathy, 5:1243
 Pancreas, insulin-secreting adenomas of, 5:1230
 Pancreatitis
 acute
 control of pain, 5:1087
 oliguria with, 4:445
 regional-block therapy, 5:1182
 benign, regional-block therapy for, 5:1184
 biliary tract disease with, 4:441, 443
 after cholecystectomy, 5:529-531
 cholecystitis with, 5:521
 chronic relapsing, control of pain of, 5:1088, 1089
 gallstones and, 5:496, 497
 magnesium deficiency with, 5:671
 Para-aminosalicylic acid therapy for tuberculous pericarditis, 4:143-144
 Paragranuloma, *see* Hodgkin's disease
 Parahemophilia
 diagnosis of, 5:22
 surgical care in, 5:77-78
 therapy for, 5:51
 Paraldehyde poisoning, 5:646
 Paralysis with neuropathy, 5:1244-1247, 1261; *see also* Bell's palsy
 Paramethadione
 dosage and preparation of, 6:1228
 epilepsy and, 6:1225
 side-effects of, 6:1226-1227
 Parasitic diseases of the liver, 6:121, 153-164
 Parasitic infestation, urticaria with, 5:830
 Parathyroid adenoma, stone analysis in, 4:479
 Parathyroid glands in renal failure, 6:1047-1048
 Parenchymal disease, pulmonary, 6:32, 33, 40-42
 Paresthesias
 "acroparesthesias," 5:1211
 as drug side-effect, 5:1296
 neuropathic, 5:1217, 1219, 1220, 1223, 1227, 1246, 1253
 Parkinson's disease
 analysis of disability in, 5:257-282
 diagnosis of, 5:258-264
 medical treatment of, 5:255-256, 283-300
 physical therapy and exercise in, 5:288-289
 psychotherapy in, 5:299
 rehabilitation in, 5:1003-1009
 self-care in, 5:277-278, 281-282
 surgical treatment of, 5:256, 301-315
See also specific symptoms
 Paronychium, chronic inflammation of, in diabetic, 4:80
 Patients
 acutely ill, psychological disturbances of, 6:732-745
 dying
 clergymen and, 6:897-898
 management of, 6:746-759

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

religious concerns of, 6:893-894
See also Physician-patient relationship; Special patients

Pectus excavatum, 6:39-40

Pellagra, 4:1038

Pelvic pain
 postoperative, 5:1174
 regional-block therapy for, 5:1180

Penicillamine
 chemical structure of, 4:544
 for cystinuria, 4:543, 545-547
 for lead neuropathy, 5:1243
 for poisoning, 4:737-739
 in Wilson's disease, 5:322, 323-327, 329

Penicillin
 annual deaths from reaction to, 5:782, 792
 dairy products contaminated with, 5:810
 skin testing for allergy to, 5:796, 800, 809

Penicillin therapy
 hypersensitivity to, and acute pericarditis, 4:152
 in meningococcal meningitis, 4:934
 in purulent pericarditis, 4:139-141
 in pyogenic meningitis, 4:904-905, 920-922
 in rheumatic pericarditis of childhood, 4:193

Pentazocine, 5:1147-1148, 1149
 for relief of pain, 5:1124, 1130, 1131-1133
 labor pain, 5:1171
 postoperative pain, 5:1176
 postpartum pain, 5:1173-1174

Peptic ulcers
 control of pain, 5:1087
 corticosteroids in, 5:848-849
 as drug side-effect, 5:1109, 1269
 occult blood loss with, 5:1102
 in primary biliary cirrhosis, 6:212
 supervision of nonpsychiatric physician in case of, 6:850-852

Periadenitis aphthae, 4:564, 567-570

Periarteritis nodosa, 6:106

Pericardial fluid, 4:126
 abnormal collections of, 4:212-214, 217-219
See also Cardiac tamponade

Pericardectomy
 in constrictive pericarditis, 4:221-224
 in tuberculous pericarditis, 4:145

Pericardiocentesis, 4:148, 174-175, 177, 188-189

Pericarditis
 acute, 4:126-129, 147-148
 idiopathic, in children, 4:89-193
 of acute myocardial infarction, 4:176-179
 allergic, 4:152-153
 amebic, 4:150-151
 chemical and metabolic causes of, 4:157-159
 in children, treatment of, 4:182-195
 cholesterol as cause of, 4:158
 chronic constrictive, 4:131-134, 147, 220-221
 nonsurgical treatment, 4:166-168
 prevention, 4:163-164
 surgical treatment, 4:162, 165-166, 167, 221-224
 treatment, 4:132-133, 162-169

Effusion in, *see* Effusions—pericardial
 fungal, 4:149-150
 gout and, 4:159
 infectious, 4:135-145
 miliary gummatous, 4:151
 neoplastic, 4:159-160
 nonspecific, 4:135-138
 pain in, 4:126-127, 136, 147
 purulent (bacterial), 4:138-141
 causes, 4:149-151
 in children, 4:182-189
 identifiable bacteria in, 4:187
 primary lesions, 4:138-139
 therapy, 4:139-141, 187
 relapsing, 4:219-220
 in renal failure, 6:1052-1053
 rheumatic, in children, 4:193-194
 rheumatoid disease of childhood and, 4:194-195
 systemic disease with, 4:147-160
 traumatic, in children, 4:195
 tuberculous, 4:141-145
 in children, 4:183-189
 uremic, 4:157-158

Pericardium
 absence of, 4:126, 206-207, 208
 congenital lesions of, 4:206-209
 cysts of, 4:209
 diseases of, 4:125, 205-206
 diverticula of, 4:208-209
 effect of cholesterol on, 4:158
 fluid in, 4:126
 abnormal collection, 4:212-219
see also Pericardial fluid; Pericardiocentesis

function of, 4:125-126, 207-208
 inflammation of, *see* Pericarditis
 open drainage of, 4:219
 surgical excision of, 4:158
 tumors of, 4:209-212

Perineal pain
 postoperative, 5:1174, 1175, 1177

regional-block therapy for, 5:1184

Peripheral nerve syndromes, 5:996-1002
etiology of, 5:996
management of, 5:997-1002
prevention of, 5:997

Peripheral neurectomy to relieve pain, 5:1199

Perleche in diabetic, 4:81-82

Pernio, 4:380

Peroneal palsy, cause of, 5:1223

Pertussis immunization, complications from, 5:885

Petechia in meningococcal meningitis, 4:932, 933-934

Petit mal seizures, 6:1219
drugs effective against, 6:1224-1228

Petroleum distillates as poison, 4:697-708

Phantom pain
after amputation, 4:436-437
surgical relief of, 5:1203-1204

Phelantin and epilepsy, 6:1224

Phenacetine
addiction, 6:714
therapy for pain, 5:1105-1106
See also A.P.C. therapy for pain

Phenazocine, 5:1147, 1148

Phenformin in maturity-onset diabetes in obese, 4:1187-1189

Phenobarbital, 6:1187
dosage and preparation of, 6:1228
effective against grand mal and focal-motor seizures, 6:1222-1223
side-effects of, 6:1126

Phenol blocks
in degenerative neurologic disease, 5:1006
in spinal cord injuries, 5:965-968

Phenothiazines
in Huntington's disease, 5:336-340
for labor pain, 5:1169
in Parkinson's disease, 5:293, 296
in Sydenham's chorea, 5:353-354
See also Methotrimeprazine

Phenotolamine in shock, 4:243, 246, 248-250

Phenotype, 4:841

Phenylbutazone therapy for pain, 5:1108-1109, 1118

Phenylephrine for shock, 4:246, 290

Phenylpyrazole therapy for pain, 5:1107-1109

Phenylramidol therapy for pain, 5:1118

Phosphate
inorganic, for renal calculi, 4:494-503
in treatment of metabolic acidosis, 5:650

Phospholipids, 6:1309-1310

Photoocoagulation in diabetic retinopathy, 4:69-70

Photosensitization in drug allergy, 5:803

Physician-patient relationship, 6:614, 646-647
with dying patients, 6:752-758
supervision for nonpsychiatric physician in, 6:842-856
teacher-student relationship vs., 6:658-660
See also History taking; Psychotherapy

Physiotherapy in reduction of airway obstruction, 4:1173-1174

Pia-glial membrane, 4:877

Pickwickian syndrome, 4:1164

"PIE" syndrome, 4:153

Piminodine, 5:1144, 1145

Piperidine derivatives, varieties of, 5:1143-1145

Piperidyl compounds in Parkinson's disease, 5:293-295

Pituitary
growth-affecting diseases of, 5:139-152
TSH regulation by, 6:451

pK of barbiturates, 4:679-682

Placebo response
positive, opiate dependence and, 5:1128
of postoperative patient, 5:1156

Plague vaccine, 5:887

Plasma fluids, 5:620-621

Plasma for shock, 4:265, 328, 1214, 1219

Plasma-protein binding, 4:584

Plasma thromboplastin antecedent (PTA) deficiency
diagnosis of, 5:22-23
surgical care in, 5:74

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

therapy for, 5:50

Plasmapheresis in macroglobulinemia, 5:457-458

Plastic surgery for burns, 4:1304-1312

Platelets, disorders of, 5:27-30, 423-442
oral surgery in, 5:95-96

Plumbism, 4:710-713, 718, 720, 723-725

Plummer's disease (autonomous hyperfunctioning nodule), 6:508-509

Pneumonia
acidosis from 5:653
rheumatic, 6:107

Pneumonitis
from poisoning, 4:706-707
uremic, 6:107

Poisoning
alkali, 4:729-733
antidotes for, 4:605, 616-624
barbiturate, 4:679-695
as cause of metabolic acidosis, 5:646
cosmetic, 4:643-646
disinfectant, 4:641-642
excretion in, 4:606-607
from household cleaning agents, 4:633-641, 731-733
insecticide, 4:626-632
iron, 4:671-677
lead, 4:710-728
mercury, 4:732-739
non-oral, 4:614-615
petroleum distillate, 4:697-708
salicylate, 4:648-669
from solvents, 4:642-643
treatment of
complications, 4:609-614
non-oral poisoning, 4:614-615
specific measures, 4:599-607
supportive, 4:607-609

See also Toxic neuropathies

Poliomyelitis, respiratory failure in, 6:33, 113

Polyarteritis, drug-induced, 5:805

Polycythemia
neuropathy with, 5:1267
vertigo and, 6:572, 575

Polymyositis, drug-induced, 5:805

Polyneuritis, 5:1211
bowel and bladder care in, 5:1214
diabetic, 5:1227-1228
respiratory failure in, 6:33
See also Neuropathies

Polyneuropathy, see Neuropathies

Pompe's disease, 4:1002

Porphyria, as metabolic neuropathy, 5:1231-1232

Portal hypertension, 6:175-190

definition of, 6:175
in primary biliary cirrhosis, 6:211

Postcholecystectomy syndrome, 5:531

Posterior tibial neuropathy, 5:1224-1225

Postinfarction syndrome, 4:178-179

Postinfectious neuropathies, 5:1264-1265
respirator and airway care with, 5:1265

Postmenopausal osteoporosis, see Osteoporosis—menopausal

Postoperative pain
control of, 5:1088
in gynecologic patients, 5:1174-1177
nature of, 5:1174-1175
unpredictability, 5:1155-1156
oxymorphone for, 5:1142, 1176
treatment of, 5:1095, 1115, 1154-1163
regional-block therapy, 5:1183, 1185

Postpartum pain
analgesics for, 5:1172-1174
control of, 5:1088
treatment of, 5:1095, 1115, 1118

Postpericardiotomy syndrome, 4:170-176, 195

Postural hypotension, vertigo and, 6:571-572, 574

Potassium
basic considerations for, 5:663-664
deficiency of, 5:664-667
acidosis from, 5:653
alkalosis from, 5:657, 659, 665
excess of, 5:667-669
magnesium and, 5:663
wasting, management of, 4:518

Pregnancy
defibrillation syndromes in, 5:401-422
gallstones and, 5:488, 497
gonococcal arthritis in, 6:1133
hemorrhage in, 5:720-721
hydramnios in, 5:725
hydrops fetalis in, 5:725
hyperthyroidism in, 6:509-511, 513
immunizations in, 5:881
nausea and vomiting in, 5:714-715
pernicious vomiting, 5:1252
neuropathy with, 5:1220, 1223
oligohydramnios in, 5:724-725
surgery in, water and electrolyte disturbances from, 5:723-724
toxemia of, 5:716-720
water and electrolyte maintenance in, 5:715-716

See also Abortion; Labor; Labor pain; Postpartum pain

Premarital help by clergymen, 6:896-897
Prematurity, mental retardation and, 4:754-756
Primaquine, hemolytic anemia from, 5:794, 795
Primary herpes with oral ulcers, 4:555-561
Primidone
 dosage and preparation of, 6:1228
 epilepsy and, 6:1223
 side-effects of, 6:1226-1227
Progeria, 5:238
Projective tests, 6:870-871
Prostate, enlargement of, and renal failure, 6:933-934
Prostheses, 5:903-905
 definition of, 5:900-901
 fitting of, 5:1050-1051
 improvements in, 5:1055
 for lower extremity amputations, 4:421-425, 427-439; *see also* Amputations
Protein metabolic neuropathies, 5:1233-1234
Protein therapy, for deficiency neuropathy, 5:1259
"Prothrombin complex"
 diagnosis of, 5:22-23
 surgical care in, 5:75
 therapy for, 5:50-51
Pruritis
 anaphylactic, 5:783, 784
 antihistamines for, 5:811, 839-840
 in drug allergy, 5:803, 811
 in uremia, 6:1045
 in urticaria, 5:825
Pseudohermaphroditism, male, 5:201-202, 214-215
Pseudohypothyroidism, 4:1010
Pseudomonas aeruginosa
 in burn wounds, 4:1256, 1257, 1259-1260, 1284
 urinary tract infections with, 4:1164
Pseud retardation, 4:747, 749-762, 794-796, 801-818
 associated with epilepsy, 4:801-818
 non-neurologic, 4:749-762
 speech disorders causing, 4:794-796
Pseudoxanthoma elasticum, 5:33, 447
Psoriatic arthritis, 5:1011, 1015
Psychiatric disorders in uremia, 6:1014
Psychiatric complications of epilepsy, 6:1247-1248
 denial of illness, 6:1257-1258
 groups of epileptic problem patients, emotional conditions, 6:1251-1253
 family reactions, 6:1254-1255
 hysteroepilepsy, 6:1251
 iatrogenic illness, 6:1255, 1258-1260
 mental deficiency, 6:1253
 organic brain disease, 6:1253
 seizure as problem, 6:1249-1251
 status epilepticus, 6:1254-1255
 neurosurgical indications, 6:1258
 social reactions, 6:1255-1256
 withdrawal seizures, 6:1256-1257
Psychiatric patients, incidence of somatic complaints in, 6:652
Psychiatric treatment
 in atopic dermatitis, 5:875
 in hereditary hemorrhagic disease, 5:111-124
 in Huntington's disease, 5:340-342
 of menopausal women, 5:554, 561, 587-595
 in Parkinson's disease, 5:299
 in urticaria, 5:830-831
Psychologic examination of physically impaired persons, 5:896-897
stroke patients, 5:987-988
Psychological disturbances in ill patients, 6:732-745, 866-869
Psychologists, clinical, 6:866-884
 function of, 6:869-871
Psychometric tests, 6:870-871
Psychosis
 corticosteroids and, 5:850
 differential diagnosis between neurosis and, 6:877-879
 in the obese, 4:113-116
 See also Schizophrenia
Psychosomatic disorders, diagnosis of, 6:872-873, 879-881
Psychotherapy
 in alcoholism, 6:764-765, 768-772
 for burned patient, 4:1291-1302
 drugs in, 6:790-791, 793-805
 family, 6:783-789, 806-807, 813-819

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

history taking as, 6:662-663
in medical office, 6:777-792
for mentally retarded, 4:778-779
for obesity, 4:1121-1122, 1158-1159
supervision of nonpsychiatric physician and, 6:842-856
See also Group therapy

Psychotropic drugs, *see* Drugs—psychotropic

Puberty in males, delayed onset of, 5:192-195

Pulmonary complications in burn patients, 4:1264-1279

Pulmonary infarction in shock, 4:309

Pulmonary infiltrative disease, cor pulmonale and, 6:250

Pulsus paradoxicus, 4:130-131

Pupillogram, 6:1269-1271

Purine-pyrimidine metabolism disorders, 4:1036-1037

Purpura
anaphylactoid, 5:449-453, 803
as drug reaction, 5:1103
due to vascular lesions, 5:30-37
factitial, 5:460
fibrinolytic, 5:27, 384
Henoch-Schönlein's, 5:33-35, 449-453, 803, 853
hyperglobulinemia, 5:459
nonthrombocytopenic, 5:443-461
psychogenic, 5:459-460
pulmonary, 6:104
senile, 5:453-454
thrombocytopathic, 5:423-440
thrombocytopenic, 5:805

Pyelography in renal failure, 6:1031

Pyelonephritis, 6:925
diabetic nephropathy and, 4:40
management of, 5:630
potassium deficiency in, 5:666
pyloric stenosis, potassium depletion with, 5:665
treatment of, 4:519

Pyoderma in diabetic, 4:76, 79

Pyridoxine
dependency on, 4:1037-1038
for drug-induced neuropathy, 5:1237-1238, 1239
in oxaluria, 4:525, 526-527

Pyruvic acid paste, 4:1305-1306

Quinacrine and epilepsy, 6:1225

Quinolines in treatment of dermatitis, 5:872, 877

Rabies vaccine, 5:887

Radial neuropathy, 5:1217-1218

Radiation, lung damage from treatment of, 6:110

Radiculitis with gout, 5:1230

Radiculopathies, *see* Peripheral nerve syndromes

Radioactive iodine uptake (RAIU), 6:444-447, 448

Raynaud's disease
feet in, 4:357-358
hands in, 4:357-358
smoking with, 4:354, 367
supportive measures in, 4:367
with trophic changes, 4:367-368
local therapy, 4:267-268
vasodilator drugs, 4:378-380, 382

Refraction, changes in, from diabetes, 4:62

Refractory seizures, treatment of, 6:1229-1230

Refsum's disease, 5:1211, 1232-1233

Regional-block therapy, 5:1180-1196
for Bell's palsy, 5:1282-1283
development and current use of, 5:1180-1182
efficacy of, 5:1191-1193
implementation of, 5:1182-1184
for labor pain, 5:1168
for neuralgia, 5:1274
requirements for effective, 5:1194-1195
types available, 5:1184-1191

Regression in acute illness, 6:732-736

Rehabilitation
concept and scope of, 5:891-892
early mobilization in, 5:908
evaluation process in, 5:893-899
need for special centers for, 5:949-950, 970
See also specific topics and organs

Reinforcers, positive, narcotics as, 5:1124

Reiter's syndrome, 5:1011, 1015; 6:1140-1145, 1150, 1151

Religion and care of patient, 6:885-889

Renal colic, acute pain of, 5:1086, 1087, 1095

Renal disease
acidosis in, 5:645-646
treatment, 5:651-652
dietary sodium in treatment of, 5:626-634

magnesium deficiency and, 5:671

magnesium excess and, 5:673

See also specific renal disorders

Renal failure
after amphotericin B therapy, 4:953
chronic
complications, 4:40-41, 102

diabetic neuropathy and, 4:35-40
 edema in, 4:38
 hypertension in, 4:37-38
 pericarditis and, 4:157-158
 protein balance in, 4:37
 serum albumin level in, 4:38-39
 water and electrolyte balance,
 4:35-37

in cirrhosis, 6:200-203
 diabetic nephropathy and, 4:32-34
 differential diagnosis of, 6:927-928
 nomenclature of, 6:927
 pathophysiology of, 6:934-935
 from poisoning, 4:609-610, 664, 737
 recovery after, 6:949-951
 treatment of, 6:923-924, 936-949
 dialysis, 6:946-949, 1054-1063
 diets, 6:924, 938-939, 1053-1054

See also Uremia

Renal insufficiency, chronic, uremia
 and, 5:1231

Renal stones, *see* Kidney stones

Renal tubular acidosis, 5:646
 magnesium deficiency in, 5:671
 potassium depletion in, 5:666
 treatment of, 5:652

Rendu-Osler-Weber disease, 5:33, 444-447

Respiration
 in burn patients, 4:1263-1279
 irregularity of, in meningitis, 4:1175-1177
 mechanical aids to, 4:1175-1177
 in obese patients, 4:1162-1164

Respirator care, *see* Airway and respiratory care of neuropathic patient

Respirators, *see* Ventilation—equipment for

Respiratory acidosis, 5:653-655

Respiratory alkalosis, 5:660-661
 in surgical patients, 5:711-713

Respiratory depression, 6:31, 83
 antidotes to, 5:1149-1150, 1168
 labor and, 5:1167, 1168, 1171
 neuropathy and, 5:1244, 1253-1254
 postoperative; 5:1155-1159, 1175
 from potent analgesics, 5:1140, 1142,
 1144, 1147, 1148

Respiratory failure
 definition of, 6:33
 as emergency, 6:11
 obstructive
 aerosol therapy, 6:361-370
 cor pulmonale in, 6:248-260
 definition of, 6:12, 233
 hypoventilation and, 6:83
 management of secretions, 6:297-300, 353-354
 medications in, 6:346-360
 recognition of, 6:47
 respiratory acidosis and, 6:98
 tests for, 6:233-247
 therapy for infections, 6:322-324, 354

tracheal intubation and tracheotomy
 in, 6:47-60

restrictive, 6:26-46
 definition of, 6:12, 26, 103
 disorders producing, 6:32-42
 I.P.P.B. in, 6:102
 medication in, 6:103-117
 obstructive disease combined with,
 6:238-239
 oxygen therapy in, 6:111-112
 pulmonary function in, 6:13, 27-32

See also specific diseases

Respiratory reactions in allergy, 5:783
 in drug allergy, 5:805

Respiratory stimulants, 6:346-350

Respiratory system
 functions of, 5:918-919
 impairment of, 5:919-921
 evaluation of those disabled,
 5:921-923
 management, 5:924-927
 physical medicine techniques,
 5:927-929

normal mechanisms of, 6:15-18

See also Lungs; Respiratory failure; Tuberculosis—pulmonary; Ventilation

Rest pain in occlusive arterial disease,
 4:113, 377, 387

Retardation, mental
 amino acid metabolism disorders
 and, 4:1011, 1019-1029
 behavioral signs of, 4:791-794

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

beriberi and, 4:1038
 calcium metabolism disorders and, 4:1007-1011
 carbohydrate metabolism disorders and, 4:1039, 1042-1043
 cation-anion metabolic disorders and, 4:1039, 1042-1043
 chronic idiopathic hypoparathyroidism and, 4:1008-1010
 congenital lysing intolerance and, 4:1030-1031
 cretinism and, 4:1044-1046
 cystathionuria and, 4:1034-1035
 differential diagnosis of, 4:773-775
 galactosemia and, 4:1003-1005
 gargoylism and, 4:1005-1006
 genetic, 4:837-851
 glycogen disease and, 4:1001-1003
 hereditary fructose intolerance and, 4:1003
 homocystinuria and, 4:1031
 hydroxykynureninuria and, 4:1034
 hyperglycemia and, 4:1029
 hypervalinemia and, 4:1029-1030
 hypoglycemia and, 4:998-1001
 hypopituitarism and, 4:1046
 idiopathic infantile hypercalcemia and, 4:1007-1008
 irremedial organic, 4:748
 insulinoma and, 4:1001
 kwashiorkor and, 4:1036
 lipid metabolism disorders and, 4:1011, 1012-1018
 maple syrup urine disease and, 4:1030
 mental institutions and, 4:834-836
 metabolic and endocrine causes of, 4:987-1047
 methionine malabsorption and, 4:1033
 misdiagnosis of, causes of, 4:750-753
 nephrogenic diabetes insipidus and, 4:1046
 oxidation-reduction metabolic disorder and, 4:1043-1044
 pellagra and, 4:1038
 pernicious anemia and, 4:1038-1039
 phenylketonuria and, 4:1031-1033
 pseudo, *see* Pseudoretardation
 psychologic, 4:747-748
 psychological evaluation of, 4:763-765
 purine-pyrimidine metabolism disorders and, 4:1036-1037
 pyridoxine dependency and, 4:1037-1038
 remedial, 4:747
 as sequelae of meningitis, 4:983
 speech in, 4:787-791
 terminology for, 4:743-744
 tests for, 4:763-770, 793-794
 training programs for, 4:829-836
 treatment of, 4:745-747, 819-827, 987
 types of, 4:747-748
 tyrosinosis and, 4:1034
 urea cycle disorders and, 4:1035-1036
 vitamin metabolism disorders and, 4:1037-1039, 1040-1042
 Wilson's disease and, 4:1039, 1042
 Reticulocytosis of alcoholics, 5:1250
 Retina, detachment of, in diabetes, 4:70-72
 Retinopathy, diabetic, 4:63-70
 pituitary suppression in, 4:64-65
 by stalk section, 4:67-69
 Reye's syndrome, 4:1005
 Rheumatic disease, phenylpyrazole therapy for, 5:1107-1108
 Rheumatic fever
 panniculitis of, 4:153-155
 pericarditis of, 4:125, 153-155
 in children, 4:193-194
 penicillin therapy, 4:193
 steroid therapy, 4:154, 193-194
 Rheumatoid arthritis
 chronic pain of, 5:1086, 1088
 median-nerve trauma and, 5:1220
 neuropathy with, 5:1269-1270
 with pericarditis, 4:156
 in children, 4:194-195
 pulmonary involvement in, 6:106, 112
 rehabilitation in, 5:1011-1014, 1016-1019
 side-effects of therapy for, 5:1101
 Rheumatoid spondylitis, 6:106
 Rhinitis, allergic
 antihistamines for, 5:838, 839, 840-841, 842
 corticosteroids for, 5:844
 in food allergy, 5:853
 Rhinorrhea
 as drug reaction, 5:1103
 meningitis and, 4:978
 Rhizotomy to relieve pain, 5:1199-1200, 1205
 Riedel's struma, 6:492-495
 Ringer's lactate for burn therapy, 4:1222, 1224
 Rinne test, 6:593, 599
 Roentgenograms in epilepsy, 6:1195
 Roman Catholic patients, 6:894
 Rotch's sign in acute pericarditis, 4:128

Rubella, arthritis with, 6:1148-1149, 1151
Rubella vaccine, complications from, 5:886
Ruptured intracranial saccular aneurysm
 symptoms of, 5:974-975
 See also Stroke patients

Salicylamide therapy for pain, 5:1103-1104

Salicylates
 poisoning from, 4:648-649; 5:646, 652
 in treatment of pain, 5:1096-1103
 analgesic combinations, 5:1117-1118, 1129
 side-effects, 5:1101-1103, 1104, 1118

Sarcoidosis
 cardiac involvement, 4:151
 treatment of, 6:109-110

Scapula, unstable, 5:1217

Schistosomiasis of the liver, 6:160-163

Schizophrenia
 management of medical illness in, 6:695-703
 obesity and, 4:1113-1116
 process of decompensation in, 6:700-701
 psychotropic-drug hazards in, 6:795
 sociopathy compared to, 6:709-710

Schoenlein-Henoch's disease, 6:928

Sciatic neuropathy, 5:1221-1222

Scleroderma, pulmonary disturbances in, 6:105

Sclerosis
 amyotrophic lateral, 6:113
 multiple, vertigo from, 6:579-585

Scopolamine (1-hyoscine) for labor pain, 5:1166-1167, 1168-1169

Scurvy, 5:31, 454-455

Seborrhea in Parkinson's disease, 5:255, 275-276, 281

Seborrheic dermatitis
 with atopic dermatitis, 5:872, 877
 differential diagnosis of, 5:866-867

Sedation for labor pain, 5:1171

Sedatives in treatment of pain, 5:1115, 1116, 1117, 1119

side-effects of, 5:1118, 1136

Seizures, 6:1179-1181
 febrile convulsions, 6:1182-1189
 major, 6:1217-1218, 1222-1224, 1228-1229
 minor, 6:1218-1228

Sensory deprivation and immobility, 6:649, 744

Septic shock, 4:271, 321-344, 907-909
 respiratory alkalosis in, 5:712-713

Septicemia in meningococcal disease, 4:931

Serum sickness-type reactions
 allergic mechanisms in, 5:780
 to drugs, 5:803-804, 811
 to immunizations, 5:882

Shock
 acid-base correction in, 4:295
 blood gases in, 4:296
 cardiogenic, 4:299-318
 clinical management of, 4:277-279, 282-293
 hemorrhagic, 4:256-271, 274-276
 oliguria and, 4:294, 296-297
 peripheral vascular failure in, 4:288-289
 plasma for, 4:265, 328, 1214, 1219
 from poisoning, 4:610, 637, 675, 676
 prevention of, 4:343
 vasodilators in, 4:243-254, 295, 308-309, 312
 vasopressors in, 4:243-254, 294-295, 306-308
 volume expanders in, 4:293-294
 See also Trauma; *specific types of shock*

Short-acting block therapy, 5:1184-1185

Shoulder dislocation, neuropathy from, 5:1216

Shoulder rigidity in Parkinson's disease, 5:262, 279-280

Silicosis, treatment of, 6:107-108

Silico-filler's disease, 6:108

Silver nitrate solution for burn infections, 4:1257-1258

Silver sulfadiazine for burn infections, 4:1259-1261

Sinusitis, treatment of pain of, 5:1117

Skin, Graves' disease and, 6:529-531

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

Skin grafts in burn patients, 4:1307-1311

Skin protection for neuropathic patient, 5:1213, 1232

Skin rash from drugs, 5:1107, 1108

Skin sensitivity, diminished with age, 5:1160

Skin tests
for anaphylactic reactions, 5:789, 790
for drug allergy, 5:799-800, 808-809, 827
in food allergy, 5:828, 856-857
in immunizations, 5:885-888
for insect sting reactions, 5:818-820

Smallpox vaccination
pregnancy and, 5:881
problems with, 5:876, 883-884

Social work and medicine, 6:857-865

Sociopathy
clergyman's role in, 6:890-891
definition of, 6:705-706
diagnosis of, 6:872-873, 881-884
recognition and management of, 6:704-710

Sodium
deficiency of, in surgical patients, 5:708-709
dietary, in treatment of chronic renal disease, 5:626-634
potassium depletion and, 5:665

Sodium bicarbonate in shock, 4:269

Sodium iodide solution therapy for neuropathy, 5:1246-1247

Sodium salicylate therapy for pain, 5:1099-1100, 1102

Sodium sulfate therapy
for arsenic neuropathy, 5:1241
for lead neuropathy, 5:1242-1243

Sodium thiosulphate solution therapy for neuropathy, 5:1246-1247

Soft-tissue bleeding, 5:54, 88-90

Spasmodic torticollis, surgical treatment of, 5:314-315

Spastic, speech in, 4:797

Special patients, 6:720-731
types of, 6:721

Specificity theory of pain, 5:1083-1084

Speech
causing pseudoretardation, 4:794-796
evaluation of, in disability, 5:898
mentally retarded and, 4:787-791
normal development of, 4:784-787
in Parkinson's disease, 5:276-277, 281
in spastic, 4:797
in specific diseases, 4:796-790
in stroke patients, 5:984-987

Sphincter function, disturbance of by regional blocks, 5:1181

by surgery, 5:1199

Spinal cord injuries, 5:949-970
bowel training in, 5:956-957
elective surgery in, 5:969
by level of damage (*table*), 5:951
need for rehabilitation center for, 5:949-950, 970

occupational therapy in, 5:960-962

phenol blocks in, 5:965-968

physical therapy in, 5:957-960

severe spasticity in, 5:965

sexual function in, 5:957, 968

skin care in, 5:954-955

urologic problems in, 5:955-956, 963-965, 968

Spinal stress, *see* Low back pain

Spinothalamic tractotomy to relieve pain, 5:1201

Spirometry, 6:233-239

Splenectomy in blood platelet disorders, 5:424

Splenomegaly, thrombocytopenia with, 5:434-435

Sporotrichosis, 6:1124-1126

Sprue, nontropical and diabetes, 4:50

Sputum examination, in post-burn patient, 4:1277

Stapedectomy, vertigo after, 6:612

Starling hypothesis, 4:1203, 1206

Status asthmaticus, *see* Asthma—status asthmaticus

Status epilepticus seizures, 6:1218
drugs effective against, 6:1228-1229

Steatorrhea, magnesium loss in, 5:670

Stereotoxic thalamotomy for relief of pain, 5:1206

Steroid therapy
growth retardation and, 4:1000
in idiopathic chronic insulin resistance, 4:19-21

for neuropathy
Bell's palsy, 5:1281
deficiency neuropathy, 5:1260
inflammatory neuropathy, 5:1264
vascular neuropathy, 5:1267, 1269-1270

obesity from, 4:1126

in pyogenic meningitis, 4:908

in rheumatic pericarditis, 4:154, 193-194

in shock, 4:269, 336

topical, in necrobiosis lipoidica, 4:74

in tuberculous pericarditis, 4:188

See also Corticosteroid therapy

Stomach
occult bleeding of, 5:1102

pH of, effect of buffered aspirin on, 5:1098

See also Dyspepsia; Peptic ulcers

Streptomycin therapy
in neonatal meningitis, 4:912
in tuberculous meningitis, 4:939-940
in tuberculous pericarditis, 4:144

Stroke patients
basic physiological considerations in, 5:971-973
body image in, 5:984
defining location and etiology of lesion in, 5:973-978
fractures in, 5:982-983
frozen shoulder in, 5:983-989
gauging functional loss in, 5:976-978
incontinence in, 5:984
physical rehabilitation of, 5:988-990
psychologic evaluation in, 5:987-988
spasticity in, 5:978-982
speech defects in, 5:984-987
vasomotor disturbances in, 5:983-984
wheelchairs and other devices for, 5:990-993

See also Cerebrovascular diseases

Struma lymphomatosa, *see* Hashimoto's thyroiditis

Stuart-factor inhibitor, 5:379

Subclavian steal syndrome, vertigo and, 6:571, 576

Subdural effusion, 4:906-907, 936-937
in bacterial meningitis, 4:907
surgery for, 4:977-978

Subdural taps in epilepsy, 6:1195, 1208

Sulfamylon therapy for burn infections, 4:1255-1257, 1284

Sulfobromophthalein retention and gallbladder nonvisualization, 5:501

Surgical neuropathies, 5:1217, 1218-1219, 1222

Sustained-release salicylate therapy for pain, 5:1098-1099, 1100

Suture, cranial closure premature, 4:826-827

Sweat, replacement of, in surgical patients, 5:704

Sydenham's chorea
diagnostic tests in, 5:355-357
prognosis in, 5:358-359
treatment of, 5:256, 351-360

Sympathectomy
lumbar, 4:403-404
to relieve pain, 5:1199, 1204

Sympathetic dystrophies, regional-block therapy for, 5:1184, 1185

Syringomyelia, loss of sensation in, 5:1086

Systemic allergic vasculitis, 4:147-160

Systemic infection, treatment of pain of, 5:1095

Systemic lupus erythematosus (SLE), Stuart-factor inhibitor in, 5:379

Tamponade, cardiac, 4:129-130, 147, 157

Telangiectasia, hereditary hemorrhagic, 5:444-447

Testes, diseases of, affecting growth, 5:184-204

Testicular androgen production diminished, 5:186-197
increased, 5:197-200

Testicular feminization, 5:201-202, 214-215

Tetanus
preventing recurrence of, 5:755
stages of, 5:729-730
treatment of, 5:730-756
case histories, 5:741-753
initial treatment, 5:731-733
rehabilitation, 5:754-755
of severe cases, 5:733-741

Tetanus vaccine, complications from, 5:885

Tetany
acute attacks of, 4:1009-1010
neonatal, 4:994-995
in poisoning, 4:663

Thalamic nucleus VPL for relief of pain, 5:1201-1202

Thalidomide-induced neuropathy, 5:1239-1240

Thallium neuropathy, 5:1246-1247

Thiamine therapy for deficiency neuropathy, 5:1251-1255, 1260

Thigh, effect of neuropathy on, 5:1223

Thoracentesis in postpericardiotomy syndrome, 4:174

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-688, July; pages 869-1070, September; pages 1071-1374, November. Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November. Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

Thoracic anterolateral cordotomy to relieve pain, 5:1200

Thoracoplasty, respiratory failure after, 6:37

Thoracotomy, respiratory failure after, 6:36-37

Thought disorders, diagnosis of, 6:872, 874-877

Throat, pain in, surgical relief of, 5:1205

Thromboangiitis obliterans anticoagulants in, 4:358-359 local care of extremities in, 4:354-357 neuropathy with, 5:1267 physical activity in, 4:351-353 smoking and, 4:353-354 with trophic changes, 4:361-365

Thrombocytopenia, 5:440-441

Thrombocytopathia in uremia, 6:1038

Thrombocytopenia, 5:27-29 from phenylpyrazoles, 5:1108 in uremia, 6:1038

Thromboembolic disorders, complications from drug therapy in, 5:372-376

Thrombophlebitis from dextropropoxyphene, 5:113

Thrush in diabetic, 4:81

Thyroid, diseases of, growth-affecting, 5:153-167

Thyroid acropachy, 6:516

Thyroid gland diagnostic tests for diseases of, 6:441, 443-461 iodine organification in, 6:447-449 regulation of activity of, 6:450-453 thyroxine and triiodothyronine synthesis in, 6:443

Thyroid hormones in blood, 6:454-459 effects of, 6:460-461

Thyroidectomy in hyperthyroidism, 6:497-499 with ophthalmopathy, 6:528

Thyroiditis, 6:474-496 auto-immune, 6:484-492 classification of, 6:474 infectious, 6:474-475 subacute nonsuppurative, 6:475-484

Thyrotoxicosis Achilles tendon reflex in, 6:461 albumin catabolism in, 6:460 triiodothyronine suppression test in, 6:453

Thyrotoxicosis factitia, 6:513

Thyrotropic hormone (TSH), 6:450-453

Tic douloureux, regional-block therapy for, 5:1184, 1185

Tinea pedis in diabetic, 4:82-83

Tineal's sign with neuropathy, 5:1220

Tissue irritation from dextropropoxyphene, 5:1113

Tissue pressure, pain from, 5:1174

Tobacco-alcohol amblyopia, 5:1260-1261

TOCP neuropathy, *see* Triorthocresyl phosphate neuropathy

Tolazamide in maturity-onset diabetes in obese, 4:1187-1190

Tolbutamide for maturity-onset diabetes in obese, 4:1187-1190

Toothache, treatment of, 5:1095

Torticollis, spasmotic, surgical treatment of, 5:314-315

Toxemia of pregnancy, defibrillation and, 5:420

Toxic-complex type of reaction, fundamental mechanism of, 5:779

Toxic neuropathies, treatment of general scope, 5:1236-1237 varieties of neuropathies, 5:1240-1247

Toxic synovitis of the hip, 6:114-115

Tracheostomy, 4:1174-1175; 6:50-54, 72-73

Tractotomy to relieve pain, 5:1200-1201

Tranquilizers for children, 4:777 in treatment of pain, 5:1115, 1116, 1117, 1119 labor pain, 5:1166 postoperative pain, 5:1162 side-effect, 5:1136 substituted for narcotics, 5:1129

See also Drugs—psychotropic

Transfusion exchange, *see* Exchange transfusion

Translocation in genetics, 4:838, 841, 842

Transplantation, *see* Kidney—transplantation of

Transplantation-rejection phenomena, 5:780

Trauma surgical, 5:1157 treatment of pain of, 5:1095 regional-block therapy, 5:1185

See also specific traumas

Traumatic and compressive neuropathies, treatment of, 5:1215-1225, 1234

Traumatic injury, acute pain of, 5:1086

Tremor in Parkinson's disease, 5:260-273, 318

Cumulative Index / 1407

surgical relief of, 5:311-312

Triceps skinfold thickness, measurement of, 4:1097-1098
in children, 4:1155-1156
table of standards for, 4:1098-1099

Trigeminal nerve alcohol block, 5:1182, 1183-1184, 1274

Trigeminal neuralgia, 5:1272-1274
medical treatment of, 5:1272-1273
surgical relief of, 5:1204-1205, 1273-1274

Trigger point procaine block therapy, 5:1183, 1187

Triglycerides and blood lipids, 6:1306-1309

Trimethadione
dosage and preparation of, 6:1228
epilepsy and, 6:1225
side-effects of, 6:1226-1227

Triorthocresyl phosphate (TOCP) neuropathy, 5:1243-1245
treatment of paralysis in, 5:1244

Trisomy, genetic
Klinefelter's syndrome, 4:842, 843, 847-848
Turner's syndrome, 4:842, 843, 847-848; 5:219-226
See also Down's syndrome

Trunk rigidity in Parkinson's disease, 5:263-264

Tuberculin skin test reaction, 5:780

Tuberculosis
as cause of meningitis, 4:947
pulmonary, corticosteroids and, 5:850
silicosis as predisposing to, 6:107-108

Tuberculous arthritis, 6:1117-1123
in children, 6:1113-1114

Tumors
adrenal, masculinizing, 5:175, 177-179
affecting food control center, 4:1126, 1128
brain, 4:946-947
malignant, *see* Cancer; Malignant tumors
ovarian, 5:209-214
of pericardium, 4:209-212
pseudo-, hemophilic, 5:90-91
vertigo and, 6:578-579, 613

Turner's syndrome, 4:842, 843, 847-848; 5:219-226

Typhus vaccine, 5:887

Tyrosinosis, 4:1034

Ulcers
corneal, due to surgery, 5:1204
of feet
in arterial occlusion, 4:354-357, 361-367, 375-376
in diabetes, 4:56-57, 75-76, 78, 111-118
from prosthesis, 4:436
in Raynaud's disease, 4:357-358, 367-368
trophic, 5:1222, 1227, 1229

Gastrointestinal, in meningitis, 4:974
intestinal, from mefenamic acid, 5:1109
with necrobiosis lipodica, 4:74

oral, acute, 4:558-559, 561, 563, 567-570
peptic, *see* Peptic ulcers

Ulnar neuropathy, 5:1218-1220

Ultrasonic therapy, 5:910-911

Ultrasound in pericardial effusion, 4:197-204

Unilateral cordotomy to relieve pain, 5:1200-1201

Upper extremity neuropathies, treatment of, 5:1215-1221

Upper extremity rigidity in Parkinson's disease, 5:261-262, 280

Upper root neuropathy, 5:1215-1216

Urea-complexed salicylate therapy for pain, 5:1099

Urea cycle disorders and mental retardation, 4:1035-1036

Uremia
acidosis and, 5:645-646
bleeding in, 5:379-380
hypocalcemia in, 5:678-680
metabolic defects of, 6:924
metabolic manifestations of, 6:1044-1050
as metabolic neuropathy, 5:1231
pericarditis with, 4:157-158
treatment of chronic, 6:1036-1063
use of drugs in, 6:1011-1035
See also Azotemia

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

Urethral scarring, renal failure and, 6:933-934

Urethritis, Reiter's syndrome with, 6:1140, 1142-1143

Uric acid kidney stones, 4:470, 472-473, 531-536

Urinalysis in epilepsy, 6:1208

Urinary bleeding and fibrinolysis, 5:389-390

Urinary tract, postoperative pain in, 5:1174

Urine flow in shock, 4:296-297

Urticaria, 5:825-836

- anaphylactic, 5:783
- in drug allergy, 5:802, 811, 826-827
- as drug reaction, 5:1103, 1107, 1112
- genesis of lesions of, 5:825-826
- incidence of, 5:82
- in insect sting reactions, 5:815
- nonallergic, 5:775
- treatment of, 5:826-835
- antihistamines, 5:831-833, 834, 835, 838, 841
- corticosteroids, 5:833, 844

Uterus, "Couvelaire," 5:409

Vaccinations, *see* Immunizations

Vaginal pain, postoperative, 5:1174, 1177

Vaginal smear in regulation of hormone dosage, 5:554-558

Vascular disease

- menopause and, 5:581-586
- pulmonary, cor pulmonale and, 6:250-251

Vascular failure, peripheral, in shock, 4:288-289

Vascular insufficiency

- peripheral, treatment of pain of, 5:1095
- vertigo from, 6:568-576, 611-612

Vascular (ischemic) neuropathies, 5:1222-1223, 1266-1270

Vasculitis

- drug-induced, 5:805
- vertigo and, 6:573

Vasoconstriction, peripheral, intra-venous injections and, 5:1157

Vasodilation, reflex or indirect, in arterial occlusion, 4:363-365

Vasodilator drugs

- for arterial disorders in extremities, 4:370-382
- for diabetes, 4:95-96, 115
- for shock, 4:243-254, 295, 308-309, 312

See also specific drugs

Vasomotor and vasotonic responses

- after long immobilization, 5:908

Vasopressor drugs

- for poisoning, 4:607-608, 610
- for shock, 4:243-254, 294-295, 306-308

See also specific drugs

Vasospastic diseases, *see* specific diseases

Venous pressure, central, in shock, 4:280, 333-335

Ventilation, 6:244-245

- assisted, 6:81-91
- definition of, 6:61, 81
- indications for, 6:62, 83-85
- I.P.P.B. in, 6:96-98, 311-312, 335-339

controlled, 6:61-80

- definition of, 6:61-81
- I.P.P.B. in, 6:311-317, 335, 341-342

emergency restoration of, 6:48

equipment for, 6:63-72, 90

- classification for, 6:62
- I.P.P.B., 6:92-96

hyper-, *see* Respiratory alkalosis

hypo-

- aerosol therapy, 6:368
- arterial pCO_2 and, 6:243-244
- compensatory mechanisms in, 6:81-82

See also Respiratory acidosis

perfusion abnormalities of, 6:240-243, 246

for poisoning, 4:686-687

in restrictive respiratory failure, 6:29-30

Versenate therapy for toxic neuropathies, 5:1241, 1243

Vertigo (dizziness)

- benign paroxysmal positional, 6:606-607
- definition of, 6:533-554
- from epilepsy, 6:585-587
- evaluation of, 6:594-604
- after head injury, 6:587-590, 609-611
- in Meniere's disease, 6:553, 555-557, 605-606

as metabolic problem, 6:612-613

in migraine, 6:591-593

from multiple sclerosis, 6:579-585

ocular causes of, 6:590-591

paroxysmal, 6:1275-1278

- anatomy, 6:1278-1280
- central nervous system, 6:1295-1296
- history, 6:1280-1283

labyrinth, 6:1293-1295
middle ear, 6:1292-1293
physical examination and tests, 6:1283-1292
of peripheral and central origin, 6:613-614
after stapedectomy, 6:612
treatment of, 6:614-620
from tumors, 6:576-579, 613
from vascular insufficiency, 6:568-578, 611-612
from vestibular neuritis, 6:607-608
vestibular-system criteria and, 6:604-605
from whiplash injury, 6:608-609
Vestibular neuritis, vertigo from, 6:607-608
V.I.P., syndrome, 6:721, 727-731
Viral forms of arthritis, 6:1146-1153
Visceral larva migrans, 6:157
Visceral pain
perception of, 5:1085, 1199
surgical relief of, 5:1199, 1204
Vision, loss of, in meningitis, 4:945, 980-981
Visual disorganization, diagnosis of, 6:875
Vitamin K
baseline requirement for, 5:701
deficiency of, 5:364-369
prolonged blood loss, 5:1103
Vitamin metabolism disorders and mental retardation, 4:1037-1039, 1040-1041
Vitamin therapy
for neuropathy
deficiency neuropathy, 5:1250-1259
diabetic polyneuritis, 5:1228
drug-induced neuropathy, 5:1237-1238, 1239
metabolic neuropathy, 5:1235
TOCP neuropathy, 5:1244
Vitamins
baseline requirement for, 5:701
in renal failure, 6:1029
Vocational evaluation in disability, 5:898-899
in cardiac disability, 5:936-937
in degenerative neurologic disease, 5:1007-1008
in peripheral nerve syndromes, 5:1002
in respiratory disabilities, 5:923
in spinal cord injuries, 5:962
Voice, parkinsonian, 5:276-277, 281
Volume expanders for shock, 4:293-294
Von Economo's disease, 5:284
Von Gierke's disease, 4:1001-1002
Von Willebrand's disease
diagnosis of, 5:23-24
surgical care in, 5:70-72
therapy for, 5:52-53
Vulvovaginitis, 4:81
Waldenstrom's macroglobulinemia, vertigo and, 6:572-573
Wallenberg syndrome, vertigo in, 6:569-570
Water
body, *see* Body water
"hard," 5:673
Water intoxication
in obstetric patients, 5:724
in surgical patients, 5:708
Waterhouse-Friderichsen syndrome, meningococcal meningitis and, 4:936
Weber test, 6:598-599
Wegener's granuloma, 6:106, 251
Weight loss for treatment of cardiopulmonary disturbances of obesity, 4:1168-1171
Wernicke-Korsakoff syndrome with deficiency neuropathy, 5:1251, 1254
Wilson's disease, 5:256, 274
prognosis in, 5:328-329
treatment of, 5:321-331
Wintergreen oil, *see* Salicylates
Wryneck, regional-block therapy for, 5:1183
Xanthine kidney stones, 4:471, 536-537
Xanthinuria, 4:536-537
Xanthoma, eruptive, 4:82
Yellow fever vaccine, 5:887

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.